<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003132" GROUP_ID="MUSKEL" ID="982300121915333867" MERGED_FROM="" MODIFIED="2009-11-12 01:05:49 +0100" MODIFIED_BY="Elizabeth Tanjong Ghogomu" REVIEW_NO="C087-R" REVMAN_SUB_VERSION="5.0.22" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2009-11-11 02:31:38 -0500" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-05-12 12:09:32 -0400" MODIFIED_BY="Lara Maxwell">Therapeutic ultrasound for osteoarthritis of the knee or hip</TITLE>
<CONTACT>
<PERSON ID="55AAB96B82E26AA2000F11BC5E70C1F3" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Anne</FIRST_NAME>
<MIDDLE_INITIALS>WS</MIDDLE_INITIALS>
<LAST_NAME>Rutjes</LAST_NAME>
<SUFFIX/>
<POSITION>Senior research fellow</POSITION>
<EMAIL_1>arutjes@ispm.unibe.ch</EMAIL_1>
<EMAIL_2>a.rutjes@crc-cesi.org</EMAIL_2>
<URL>http://www.ispm.ch/ and http://www.crc-cesi.org/</URL>
<MOBILE_PHONE>+39 389 999 36 50</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Finkenhubelweg 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP>3012</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 (0)31 631 33 28</PHONE_1>
<PHONE_2>+39 389 999 36 50</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2009-11-09 03:53:53 -0500" MODIFIED_BY="Anne Rutjes">
<PERSON ID="55AAB96B82E26AA2000F11BC5E70C1F3" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Anne</FIRST_NAME>
<MIDDLE_INITIALS>WS</MIDDLE_INITIALS>
<LAST_NAME>Rutjes</LAST_NAME>
<SUFFIX/>
<POSITION>Senior research fellow</POSITION>
<EMAIL_1>arutjes@ispm.unibe.ch</EMAIL_1>
<EMAIL_2>a.rutjes@crc-cesi.org</EMAIL_2>
<URL>http://www.ispm.ch/ and http://www.crc-cesi.org/</URL>
<MOBILE_PHONE>+39 389 999 36 50</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Finkenhubelweg 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP>3012</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 (0)31 631 33 28</PHONE_1>
<PHONE_2>+39 389 999 36 50</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6701E84582E26AA201880571E7219167" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Eveline</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Nüesch</LAST_NAME>
<SUFFIX/>
<POSITION>Research Fellow</POSITION>
<EMAIL_1>enueesch@ispm.unibe.ch</EMAIL_1>
<EMAIL_2/>
<URL>www.ispm.unibe.ch</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Finkenhubelweg 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP>3012</ZIP>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 (0) 31 631 33 28</PHONE_1>
<PHONE_2/>
<FAX_1>+ 41 (0) 31 631 35 20</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="E4898B6082E26AA200F94DADC4F681AF" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Rebekka</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Sterchi</LAST_NAME>
<SUFFIX/>
<POSITION>Research Fellow</POSITION>
<EMAIL_1>rsterchi@ispm.unibe.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Finkenhubelweg 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP>3012</ZIP>
<REGION>Bern</REGION>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 31 631 33 28</PHONE_1>
<PHONE_2/>
<FAX_1>+41 31 301 90 10</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="10779" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Jüni</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>Head of Division</POSITION>
<EMAIL_1>juni@ispm.unibe.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine</DEPARTMENT>
<ORGANISATION>University of Bern</ORGANISATION>
<ADDRESS_1>Finkenhubelweg 11</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bern</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 31 631 33 78</PHONE_1>
<PHONE_2/>
<FAX_1>+41 31 631 35 20</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2009-10-21 22:41:45 -0400" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="23" MONTH="7" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="23" MONTH="7" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="13" MONTH="10" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2001"/>
</DATES>
<WHATS_NEW MODIFIED="2009-11-11 02:31:38 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-10-12 03:27:45 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="7" YEAR="2009"/>
<DESCRIPTION>
<P>4 additional trials included</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2009-11-11 02:31:38 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="7" YEAR="2009"/>
<DESCRIPTION>
<P>Change in authors and conclusions. We updated the search and applied more strict selection criteria, which resulted in 4 additional trials and the exclusion of 2 studies previously included. We used more detailed quality assessment of component trials; use of end of trial estimates to calculate SMDs; detailed exploration of sources of variation between trials, including concealment of allocation, blinding, intention-to-treat analysis, characteristics of electrostimulation, and investigations of funnel plots; use of a random-effects model. The previous version included only one trial comparing therapeutic ultrasound with a sham intervention and found a statistically non-significant beneficial effects on pain and function, whereas this version shows a statistically significant effect on pain, although we are uncertain about the exact magnitude of the effect. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-07-16 05:34:18 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>CMSG ID C087-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="2" MONTH="5" YEAR="2001"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-02-20 09:50:20 -0500" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2009-02-20 09:48:18 -0500" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-02-20 09:48:18 -0500" MODIFIED_BY="[Empty name]">
<NAME>Institute of Social and Preventive Medicine, University or Bern</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION>
<P>Intramural grants</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2009-02-20 09:50:20 -0500" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-02-20 09:50:20 -0500" MODIFIED_BY="[Empty name]">
<NAME>Swiss National Science Foundation</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION>
<P>National Research Program 53 on musculoskeletal health (grant numbers 4053-40-104762/3 and 3200-066378)</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-11-11 17:04:59 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-11-11 02:33:03 -0500" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-10-12 03:31:04 -0400" MODIFIED_BY="[Empty name]">Therapeutic ultrasound for osteoarthritis</TITLE>
<SUMMARY_BODY MODIFIED="2009-11-11 02:33:03 -0500" MODIFIED_BY="[Empty name]">
<P>This summary of a Cochrane review presents what we know from research about the effect of therapeutic ultrasound on knee or hip osteoarthritis. The previous version of this review concluded that therapeutic ultrasound had no benefit over fake therapeutic ultrasound in pain relief and functional status. </P>
<P>The updated review shows that in people with osteoarthritis,<BR/>-Therapeutic ultrasound may be beneficial for people with osteoarthritis of the knee. </P>
<P>-Therapeutic ultrasound may improve your physical function but this finding could be the result of chance.</P>
<P>- We are uncertain about the magnitude of effects on pain relief or the ability to use your knee, because of the low quality of the evidence.<BR/>-Therapeutic ultrasound may not have any side effects: no side effects were reported, but we do not have precise information about side effects. This is particularly true for rare but serious side effects. </P>
<P>There are no studies that address the benefits of therapeutic ultrasound in people with hip osteoarthritis. </P>
<P>
<B>What is osteoarthritis and what is therapeutic ultrasound?</B>
</P>
<P>Osteoarthritis is a disease of the joints, such as your knee or hip. When the joint loses cartilage, the bone grows to try and repair the damage. Instead of making things better, however, the bone grows abnormally and makes things worse. For example, the bone can become misshapen and make the joint painful and unstable.  This can affect your physical function or ability to use your knee.<BR/>Therapeutic ultrasound means using sound waves to try and relieve pain or disability. Your doctor or physiotherapist will use a round-headed wand or probe on the skin of the painful area. Ultrasound gel is used on the wand and on your skin to make it more comfortable and help the sound waves reach the affected area. </P>
<P>
<B>Best estimate of what happens to people with osteoarthritis who have had therapeutic ultrasound for a duration of 2-8 weeks:</B>
</P>
<P>
<B>Pain </B>
<BR/>-People who used therapeutic ultrasound had an improvement in their pain of about 3 on a scale from 0 (no pain) to 10 (extreme pain) after using it up to 2 months.<BR/>-People who used a fake therapeutic ultrasound had an improvement in their pain of about 2 on a scale from 0 to 10 after using it up to 2 months.<BR/>Another way of saying this is:<BR/>- 37 people out of 100 who use therapeutic ultrasound respond to treatment (37%).<BR/>- 31 people out of 100 who use fake therapeutic ultrasound respond to treatment (31%).<BR/>- 6 more people respond to treatment with therapeutic ultrasound than with fake therapeutic ultrasound (difference of 6%).</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-11-11 15:11:36 -0500" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-02-18 03:59:20 -0500" MODIFIED_BY="[Empty name]">
<P>Osteoarthritis is the most common form of joint disease and the leading cause of pain and physical disability in the elderly. Therapeutic ultrasound is one of several physical therapy modalities suggested for the management of pain and loss of function due to osteoarthritis (OA).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-11-11 02:31:44 -0500" MODIFIED_BY="[Empty name]">
<P>To compare therapeutic ultrasound with sham or no specific intervention in terms of effects on pain and function safety outcomes in patients with knee or hip OA.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-11-11 02:31:47 -0500" MODIFIED_BY="[Empty name]">
<P>We updated the search in CENTRAL, CINAHL, EMBASE, MEDLINE and PEDro up to 23 July 2009, checked conference proceedings, reference lists, and contacted authors.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-03-03 06:05:48 -0500" MODIFIED_BY="[Empty name]">
<P>Studies were included if they were randomised or quasi-randomised controlled trials that compared therapeutic ultrasound with a sham intervention or no intervention in patients with osteoarthritis of the knee or hip.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-11-11 14:49:11 -0500" MODIFIED_BY="[Empty name]">
<P>Two independent review authors extracted data using standardized forms. Investigators were contacted to obtain missing outcome information. Standardised mean differences (SMDs) were calculated for pain and function, relative risks for safety outcomes. Trials were combined using inverse-variance random-effects meta-analysis.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-11-11 15:11:36 -0500" MODIFIED_BY="[Empty name]">
<P>Compared to the previous version of the review, four additional trials were identified resulting in the inclusion of five small sized trials in a total of 341 patients with knee OA. No trial included patients with hip OA. Two evaluated pulsed ultrasound, two continuous and one evaluated both pulsed and continuous ultrasound as the active treatment. The methodological quality and the quality of reporting was poor and a high degree of heterogeneity among the trials was revealed for function (88%). For pain, there was an effect in favour of ultrasound therapy, which corresponded to a difference in pain scores between ultrasound and control of -1.2 cm on a 10-cm VAS (95% CI -1.9 to -0.6 cm). For function, we found a trend in favour of ultrasound, which corresponded to a difference in function scores of -1.3 units on a standardised WOMAC disability scale ranging from 0 to 10 (95% CI -3.0 to 0.3). Safety was evaluated in two trials including up to 136 patients; no adverse event, serious adverse event or withdrawals due to adverse events occurred in either trial.<B> </B>
</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-11-11 02:32:13 -0500" MODIFIED_BY="[Empty name]">
<P>In contrast to the previous version of this review, our results suggest that therapeutic ultrasound may be beneficial for patients with osteoarthritis of the knee. Because of the low quality of the evidence, we are uncertain about the magnitude of the effects on pain relief and function, however. Therapeutic ultrasound is widely used for its potential benefits on both knee pain and function, which may be clinically relevant. Appropriately designed trials of adequate power are therefore warranted.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-11-11 17:04:59 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-11-11 15:14:45 -0500" MODIFIED_BY="[Empty name]">
<P>Osteoarthritis (OA) is an age related condition, occurring more frequently in women than in men. Its prevalence, causal associations and outcomes vary markedly according to the joint site affected (<LINK REF="REF-J_x00fc_ni-2006" TYPE="REFERENCE">Jüni 2006</LINK>). OA is characterized by focal areas of loss of articular cartilage in synovial joints, accompanied by subchondral bone changes, osteophyte formation at the joint margins, thickening of the joint capsule and mild synovitis (<LINK REF="REF-Solomon-1997" TYPE="REFERENCE">Solomon 1997</LINK>). The objectives of management of knee and hip OA are to relieve pain and to maintain or improve function.</P>
<P>Therapeutic ultrasound is one of many physical therapy modalities and can be used as part of an overall rehabilitation program (<LINK REF="REF-Rand-2007" TYPE="REFERENCE">Rand 2007</LINK>). Therapeutic ultrasound consists of high frequency vibrations (<LINK REF="REF-Hartley-1993" TYPE="REFERENCE">Hartley 1993</LINK>; <LINK REF="REF-Nelson-1999" TYPE="REFERENCE">Nelson 1999</LINK>) that can be pulsed or continuous. Pulsed ultrasound produces non-thermal effects and is generally recommended for acute pain and inflammation. Continuous ultrasound generates thermal effects (<LINK REF="REF-Rand-2007" TYPE="REFERENCE">Rand 2007</LINK>). Therapeutic ultrasound that penetrates deeply enough to increase collagen elasticity may be useful in the early stages of a flexibility program (<LINK REF="REF-Hicks-1990" TYPE="REFERENCE">Hicks 1990</LINK>).</P>
<P>The 2008 OARSI recommendations for the management of hip and knee OA state that the optimal management of OA requires a combination of non-pharmacological and pharmacological modalities, including physical therapy (<LINK REF="REF-Zhang-2008" TYPE="REFERENCE">Zhang 2008</LINK>), but does not specifically mention ultrasound as treatment adjunct. Only 1 out of 5 existing guidelines considering ultrasound actually recommended its use, but the recommendation was not based on evidence from randomised trials.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-02-18 05:25:36 -0500" MODIFIED_BY="[Empty name]">
<P>We set out to compare therapeutic ultrasound with sham or no specific intervention in terms of effects on pain and function and safety outcomes in patients with knee or hip OA and to explore whether potential variation between trials could be explained by characteristics of the ultrasound, by biases affecting individual trials or by publication bias.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-11-11 16:56:45 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-11-11 15:16:44 -0500" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-10-12 05:18:30 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised or quasi randomised controlled trials with a control group receiving a sham intervention or no intervention.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-07-28 10:09:03 -0400" MODIFIED_BY="[Empty name]">
<P>At least 75% of patients with clinically and/or radiologically confirmed osteoarthritis of the knee or hip.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-10-12 05:22:17 -0400" MODIFIED_BY="[Empty name]">
<P>Any type of continuous or pulsed therapeutic ultrasound. Phonophoresis (the use of ultrasound to enhance the delivery of topically applied drugs) or extracorporeal ultrasonic treatment (derivative of lithotripsy, the mechanical breaking up of renal stones with sound waves) were not considered. Eligible control interventions were placebo or a non-intervention control (usual care). Concurrent therapy was accepted providing it was provided to both, experimental and control groups.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-11-11 15:16:44 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Main outcomes</HEADING>
<P>Main outcomes were pain and function, as currently recommended for osteoarthritis trials (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>; <LINK REF="REF-Pham-2004" TYPE="REFERENCE">Pham 2004</LINK>). If data on more than one pain scale were provided for a trial, we referred to a previously described hierarchy of pain-related outcomes (<LINK REF="REF-J_x00fc_ni-2006" TYPE="REFERENCE">Jüni 2006</LINK>; <LINK REF="REF-Reichenbach-2007" TYPE="REFERENCE">Reichenbach 2007</LINK>) and extracted only data on the pain scale that was highest on this hierarchy:</P>
<P>1.   Global pain<BR/>2.   Pain on walking<BR/>3.   WOMAC osteoarthritis index pain subscore<BR/>4.   Composite pain scores other than WOMAC<BR/>5.   Pain on activities other than walking<BR/>6.   Rest pain or pain during the night<BR/>7.   WOMAC global algofunctional score<BR/>8.   Lequesne osteoarthritis index global score<BR/>9.   Other algofunctional scale<BR/>10. Patient's global assessment<BR/>11. Physician's global assessment</P>
<P>If data on more than one function scale were provided for a trial, we extracted data according to hierarchy presented below.</P>
<P>1.   Global disability score<BR/>2.   Walking disability<BR/>3.   WOMAC disability subscore<BR/>4.   Composite disability scores other than WOMAC<BR/>5.   Disability other than walking<BR/>6.   WOMAC global scale<BR/>7.  Lequesne osteoarthritis index global score<BR/>8.   Other algofunctional scale<BR/>9.   Patient&#8217;s global assessment<BR/>10. Physician&#8217;s global assessment</P>
<P>If pain or function outcomes were reported at several time-points, we extracted the estimate at the end of the treatment period.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>Secondary outcomes were the number of patients experiencing any adverse event, patients who were withdrawn or dropped out because of adverse events, and patients experiencing any serious adverse events between randomisation and end of follow-up. Serious adverse events were defined as events resulting in hospitalisation, prolongation of hospitalisation, persistent or significant disability, congenital abnormality/birth defect of offspring, life-threatening events or death.</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-10-12 03:35:29 -0400" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2009-10-12 03:35:29 -0400" MODIFIED_BY="[Empty name]">
<P>We searched electronic databases of CENTRAL through The Cochrane Library (http://mrw.interscience.wiley.com/cochrane/), MEDLINE and EMBASE through the Ovid platform (www.ovid.com), CINAHL through EBSCOhost, Physiotherapy Evidence Database (PEDro, http://www.pedro.org.au/), all from implementation to July 23, 2009 using a combination of keywords and text words related to ultrasound combined with keywords and text words related to osteoarthritis and a validated filter for controlled clinical trials (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>). The search strategy is presented in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> and <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-07-23 03:40:03 -0400" MODIFIED_BY="[Empty name]">
<P>We manually searched conference proceedings, used Science Citation Index to retrieve reports citing relevant articles, contacted content experts and trialists and screened reference lists of all obtained articles, including related reviews. Finally, we searched several clinical trial registries (www.clinicaltrials.gov, www.controlled-trials.com, www.actr.org.au, www.umin.ac.jp/ctr) to identify ongoing trials. The last update of the manual search was on February 02, 2009.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-11-11 16:56:45 -0500" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2009-11-11 15:18:06 -0500" MODIFIED_BY="[Empty name]">
<P>Two review authors independently evaluated all titles and abstracts for eligibility. Disagreements were resolved by discussion. We applied no language restrictions. If multiple reports described the same trial, we considered all.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-11-11 15:18:19 -0500" MODIFIED_BY="[Empty name]">
<P>Two review authors (AR and EN or RS) extracted trial information independently using a standardised, piloted data extraction form accompanied by a codebook. Disagreements were resolved by discussion. We extracted the characteristics of the therapeutic application, including type of device, head size of the probe, any specific skin or probe preparation, the frequency and duration of treatment and the total number of sessions. Other data extracted included the type of control intervention used, patient characteristics (gender, average age, duration of symptoms, type of joint), characteristics of pain, function, and safety outcomes, design, trial size, trial duration (defined as time from randomisation until end of follow-up), type and source of financial support and publication status. When necessary, means and measures of dispersion were approximated from figures in the reports. For crossover trials, we extracted data from the first period only. Whenever possible, we used results from an intention-to-treat analysis. If effect sizes could not be calculated, we contacted the authors for additional data.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-11-11 15:20:52 -0500" MODIFIED_BY="[Empty name]">
<P>Two review authors (AR and EN or RS) independently assessed randomisation, blinding and adequacy of analyses (<LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>). Disagreements were resolved by consensus. Two components of randomisation were assessed: generation of allocation sequences and concealment of allocation. Generation of sequences was considered adequate if it resulted in an unpredictable allocation schedule; mechanisms considered adequate included random-number tables, computer-generated random numbers, minimisation, coin tossing, shuffling of cards, and drawing of lots. Trials using an unpredictable allocation sequence were considered randomised; trials using potentially predictable allocation mechanisms, such as alternation or the allocation of patients according to date of birth, were considered quasi-randomised. Allocation concealment was considered adequate, if the investigators responsible for patient selection were unable to suspect before allocation which treatment was next; methods considered adequate included central randomisation and sequentially numbered, sealed, opaque envelopes. Blinding of patients was considered adequate if a sham intervention was used that was identical in appearance to the experimental intervention. Handling of incomplete outcome data was considered adequate if all randomised patients were included in the analysis (intention-to-treat principle). Finally, we used GRADE to describe the quality of the overall body of evidence (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>; <LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>), defined as the extent of confidence into the estimated treatment benefits and harms.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-11-11 16:56:45 -0500" MODIFIED_BY="[Empty name]">
<P>Continuous outcomes were summarized using standardized mean differences (SMD), with the differences in mean values at the end of treatment across treatment groups divided by the pooled standard deviation. If differences in mean values at the end of the treatment were unavailable, differences in mean changes were used. If some of the required data were unavailable, we used approximations as previously described (<LINK REF="REF-Reichenbach-2007" TYPE="REFERENCE">Reichenbach 2007</LINK>). <LINK REF="STD-Huang-2005-B" TYPE="STUDY">Huang 2005 B</LINK> had two experimental groups, which were combined using weighted averages of the point estimates and pooled standard deviations. In <LINK REF="STD-Huang-2005-A" TYPE="STUDY">Huang 2005 A</LINK> and <LINK REF="STD-Huang-2005-B" TYPE="STUDY">Huang 2005 B</LINK> the units of randomisation were patients, whereas the units of analysis were knees. We therefore inflated the standard error with the square root of the ratio of number of knees divided by number of patients to account for the correlation of knees within patients. An SMD of -0.20 standard deviation units can be considered a small difference between experimental and control group, an SMD of -0.50 a moderate, and -0.80 a large difference (<LINK REF="REF-Cohen_x002c_-1988" TYPE="REFERENCE">Cohen, 1988</LINK>; <LINK REF="REF-J_x00fc_ni-2006" TYPE="REFERENCE">Jüni 2006</LINK>). SMDs can also be interpreted in terms of the percent of overlap of the experimental group's scores with scores of the control group. An SMD of -0.20 indicates an overlap in the distributions of pain or function scores in about 85% of cases, an SMD of -0.50 in approximately 67%, and an SMD of -0.80 in about 53% of cases (<LINK REF="REF-Cohen_x002c_-1988" TYPE="REFERENCE">Cohen, 1988</LINK>; <LINK REF="REF-J_x00fc_ni-2006" TYPE="REFERENCE">Jüni 2006</LINK>). On the basis of a median pooled SD of 2.5 cm found in large-scale osteoarthritis trials that assessed pain using a 10 cm visual analogue scale (VAS) (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>), SMDs of -0.20, -0.50 and -0.80 correspond to approximate differences in pain scores between experimental and control groups of 0.5, 1.25 and 2.0 cm on a 10 cm VAS. SMDs for function were back transformed to a standardised WOMAC disability score (<LINK REF="REF-Bellamy-1995" TYPE="REFERENCE">Bellamy 1995</LINK>) ranging from 0 to 10 on the basis of a median pooled SD of 2.1 units observed in large-scale osteoarthritis trials (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>). Binary outcomes were expressed as relative risks.</P>
<P>We used standard inverse-variance random-effects meta-analysis (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>) to combine trials. We quantified heterogeneity between trials using the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>), which describes the percentage of variation across trials that is attributable to heterogeneity rather than to chance and the corresponding &#967;<SUP>2</SUP> test. I<SUP>2</SUP> values of 25%, 50% and 75% may be interpreted as low, moderate, and high between-trial heterogeneity, although the interpretation of I<SUP>2 </SUP>depends on the size and number of trials included (<LINK REF="REF-R_x00fc_cker-2008" TYPE="REFERENCE">Rücker 2008</LINK>). The association between trial size and treatment effects was investigated in funnel plots, plotting effect sizes on the horizontal axis against their standard errors on the vertical axis. We assessed asymmetry by the Egger&#8217;s test (<LINK REF="REF-Sterne-2001" TYPE="REFERENCE">Sterne 2001</LINK>). For the main analysis on pain and function, we performed analyses stratified by the following trial characteristics: concealment of allocation, use of a sham intervention in the control group, blinding of patients, blinding of outcome assessors, analysis in accordance with the intention-to-treat principle, trial size, difference in the use of analgesic co-interventions, use of concurrent treatment, specific type of ultrasound therapy (pulsed versus continuous), duration of stimulation per session, total number of sessions, duration of treatment period and source of funding. A cut-off of 200 patients was used to distinguish between small and large trials; a sample size of 100 patients per group will yield more than 80% power to detect a small to moderate SMD of -0.40 at a two-sided P value of 0.05. Then, we converted SMDs of pain intensity and function to odds ratios (<LINK REF="REF-Chinn-2000" TYPE="REFERENCE">Chinn 2000</LINK>) to derive numbers needed to treat (NNT) to cause one additional treatment response on pain or function as compared with control, and numbers needed to harm (NNH) to cause one additional adverse outcome. We defined treatment response as a 50% improvement in scores (<LINK REF="REF-Clegg-2006" TYPE="REFERENCE">Clegg 2006</LINK>), which corresponds to an average decrease of 1.2 standard deviation units (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>). With a median standardised pain intensity at baseline of 2.4 standard deviation units and a median standardised decrease in pain scores of 0.72 standard deviation units observed in large osteoarthritis trials (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>), we calculated that a median of 31% of patients in the control group would achieve an improvement of pain scores of 50% or more. This percentage was used as the control group response rate to calculate NNTs for treatment response on pain. Based on the median standardised WOMAC function score at baseline of 2.7 standard deviation units and the median standardised decrease in function scores of 0.58 standard deviation units (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>), 26% of patients in the control group would achieve a reduction in function of 50% or more. Again, this percentage was used as the control group response rate to calculate NNTs for treatment response on function. Median risks of 150 patients with adverse events per 1000 patient-years, 4 patients with serious adverse events per 1000 patient-years and 17 dropouts due to adverse events per 1000 patient-years observed in placebo groups in large osteoarthritis trials (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>) were used to calculate NNHs for safety outcomes. Analyses were performed in RevMan version 5 (Nordic Cochrane Centre, Cochrane Collaboration, Copenhagen) and STATA version 10.1 (StataCorp, College Station, Texas). All P values are two-sided.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-11-11 17:04:59 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-11-11 15:32:10 -0500" MODIFIED_BY="[Empty name]">
<P>We identified 2156 references to articles and considered 66 to be potentially eligible (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Five randomised trials in 341 patients met our inclusion criteria. Two trials evaluated pulsed ultrasound (<LINK REF="STD-Falconer-1992" TYPE="STUDY">Falconer 1992</LINK>; <LINK REF="STD-Huang-2005-A" TYPE="STUDY">Huang 2005 A</LINK>), two continuous (<LINK REF="STD-Cetin-2008" TYPE="STUDY">Cetin 2008</LINK>; <LINK REF="STD-_x00d6_zg_x00f6_nenel-2009" TYPE="STUDY">Özgönenel 2009</LINK>) and one evaluated both pulsed and continuous ultrasound as the active treatment (<LINK REF="STD-Huang-2005-B" TYPE="STUDY">Huang 2005 B</LINK>).</P>
<P>All trials used a parallel group design, in which three used a sham intervention in the control group (<LINK REF="STD-Falconer-1992" TYPE="STUDY">Falconer 1992</LINK>; <LINK REF="STD-Huang-2005-B" TYPE="STUDY">Huang 2005 B</LINK>; <LINK REF="STD-_x00d6_zg_x00f6_nenel-2009" TYPE="STUDY">Özgönenel 2009</LINK>). All but one trial (<LINK REF="STD-_x00d6_zg_x00f6_nenel-2009" TYPE="STUDY">Özgönenel 2009</LINK>) provided standardised concurrent treatment in both experimental and control groups. <LINK REF="STD-Cetin-2008" TYPE="STUDY">Cetin 2008</LINK> used hot packs and isokinetic exercise, <LINK REF="STD-Falconer-1992" TYPE="STUDY">Falconer 1992</LINK> isometric exercise, mobilising exercise, manual therapy and joint protection, <LINK REF="STD-Huang-2005-A" TYPE="STUDY">Huang 2005 A</LINK> and <LINK REF="STD-Huang-2005-B" TYPE="STUDY">Huang 2005 B</LINK> isokinetic exercise and hot packs. In addition, instruction in daily home exercises were given in the trials by <LINK REF="STD-Falconer-1992" TYPE="STUDY">Falconer 1992</LINK>; <LINK REF="STD-Huang-2005-A" TYPE="STUDY">Huang 2005 A</LINK> and <LINK REF="STD-Huang-2005-B" TYPE="STUDY">Huang 2005 B</LINK>. In the trial by <LINK REF="STD-_x00d6_zg_x00f6_nenel-2009" TYPE="STUDY">Özgönenel 2009</LINK>, it was unclear if concurrent treatment was given, with the authors stating that "no physiotherapy was prescribed prior to ultrasound treatment to either of the groups", but referring to their intervention as physiotherapy program. Therefore, we could not exclude that other physiotherapy modalities were provided in addition to ultrasound treatment.</P>
<P>Treatment parameters were insufficiently described (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). All trials used ultrasound probes with direct skin contact at 1 MHz. 1 to 1.5 W/cm<SUP>2</SUP> was the maximum intensity in trials using continuous ultrasound, 2.5 W/cm<SUP>2</SUP> in trials using pulsed ultrasound. Two trials explicitly stated the mean intensity, which was 1.5 W/cm<SUP>2</SUP> in <LINK REF="STD-Cetin-2008" TYPE="STUDY">Cetin 2008</LINK> and 1.7 W/cm<SUP>2</SUP> in <LINK REF="STD-Falconer-1992" TYPE="STUDY">Falconer 1992</LINK>. The two trials by Huang and colleagues reported that intensity was increased up to a level at which a warm sensation or a mild sting was felt, not exceeding 2.5 W/cm<SUP>2</SUP>. Only two trials reported the size of the probe used (<LINK REF="STD-Falconer-1992" TYPE="STUDY">Falconer 1992</LINK>; <LINK REF="STD-_x00d6_zg_x00f6_nenel-2009" TYPE="STUDY">Özgönenel 2009</LINK>).</P>
<P>The duration of treatment per lesion was reported to be 3, 5 and 5 minutes, the number of lesions treated per session four, three and three, respectively in <LINK REF="STD-Falconer-1992" TYPE="STUDY">Falconer 1992</LINK>; <LINK REF="STD-Huang-2005-A" TYPE="STUDY">Huang 2005 A</LINK>; and <LINK REF="STD-Huang-2005-B" TYPE="STUDY">Huang 2005 B</LINK>. From these data, we estimated that the duration of ultrasound treatment per session was 12, 15 and 15 minutes in these trials. <LINK REF="STD-Cetin-2008" TYPE="STUDY">Cetin 2008</LINK> and <LINK REF="STD-_x00d6_zg_x00f6_nenel-2009" TYPE="STUDY">Özgönenel 2009</LINK> described that the duration of ultrasound per session was 10 and 5 minutes, respectively. The median number of treatment sessions per week was 3 (range 2 to 5), the median length of the treatment period was 8 weeks (range 2 to 8).</P>
<P>All trials explicitly included patients with knee OA only, with the diagnosis based on clinical and/or radiographic evidence. The majority of patients had a clinical severity requiring simple non-surgical treatments (<LINK REF="REF-J_x00fc_ni-2006" TYPE="REFERENCE">Jüni 2006</LINK>). In one trial, 21 out of 40 patients had severity grade III or IV according to Kellgren and Lawrence, however (<LINK REF="STD-Cetin-2008" TYPE="STUDY">Cetin 2008</LINK>). In another trial, 8 out of 69 patients had received total knee arthroplasty more than 6 months before the trial started, and all patients in this study had chronic knee contractures (<LINK REF="STD-Falconer-1992" TYPE="STUDY">Falconer 1992</LINK>). One trial reported the average disease duration, which was 7 years (<LINK REF="STD-Falconer-1992" TYPE="STUDY">Falconer 1992</LINK>), two reported the average body mass index, which was 28 and 32 kg/m<SUP>2 </SUP>in <LINK REF="STD-Cetin-2008" TYPE="STUDY">Cetin 2008</LINK> and <LINK REF="STD-_x00d6_zg_x00f6_nenel-2009" TYPE="STUDY">Özgönenel 2009</LINK>, respectively.</P>
<P>Five randomised trials were excluded because a concurrent therapy was given in the ultrasound group, which was not given in the control group: ultrasound therapy, exercise and hot packs versus exercise in <LINK REF="REF-Ones-2006" TYPE="REFERENCE">Ones 2006</LINK>, treatment according to Dutch physiotherapy guideline versus behavioral graded activity in <LINK REF="REF-Veenhof-2007" TYPE="REFERENCE">Veenhof 2007</LINK>, pulsed short wave diathermy, exercise and ultrasound therapy versus pulsed short wave diathermy with different parameters, exercise and ultrasound therapy in <LINK REF="REF-Tuzun-2003" TYPE="REFERENCE">Tuzun 2003</LINK>, ultrasound therapy, transcutaneous electrostimulation and exercise versus exercise in <LINK REF="REF-Dincer-2008" TYPE="REFERENCE">Dincer 2008</LINK> and glucosamine sulfate, NSAID and ultrasound therapy versus combined traditional Chinese medicine versus glucosamine sulfate, NSAID, ultrasound therapy and traditional Chinese medicine in <LINK REF="REF-Qin-2008" TYPE="REFERENCE">Qin 2008</LINK>. Three randomised trials were excluded because ultrasound was compared to active control interventions: ultrasound therapy versus short wave diathermy or ultrasound therapy with exercise or diathermy with exercise in <LINK REF="STD-Jan-1991" TYPE="STUDY">Jan 1991</LINK>, ultrasound therapy with deep relief gel versus ultrasound therapy with standard gel in <LINK REF="REF-Yang-2005" TYPE="REFERENCE">Yang 2005</LINK>, ultrasound therapy versus phonophoresis in <LINK REF="REF-Dafinova-1996" TYPE="REFERENCE">Dafinova 1996</LINK> and <LINK REF="REF-Kozanoglu-2003" TYPE="REFERENCE">Kozanoglu 2003</LINK>, and ultrasound therapy versus shortwave diathermy or galvanic electrostimulation in <LINK REF="STD-Bansil-1975" TYPE="STUDY">Bansil 1975</LINK>, <LINK REF="REF-Kalpakcioglu-2006" TYPE="REFERENCE">Kalpakcioglu 2006</LINK> and <LINK REF="STD-Svarcova-1988" TYPE="STUDY">Svarcova 1988</LINK>. <LINK REF="STD-Bansil-1975" TYPE="STUDY">Bansil 1975</LINK> and <LINK REF="STD-Svarcova-1988" TYPE="STUDY">Svarcova 1988</LINK> were included in the previous version of this review. The <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table presents the main reasons for exclusion of other studies.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-11-11 16:31:13 -0500" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> summarises the methodological characteristics and source of funding of included trials. No trial reported adequate sequence generation or adequate concealment of allocation. Both trials by Huang et al reported the use of sequentially numbered, sealed and opaque envelopes, but they reported that envelopes were sequentially numbered I to IV, likely to represent the four comparison groups patients were allocated to in both of these trials. The envelopes should have been numbered 1 to 140 and 1 to 120 to cover the numbers of patient randomised in <LINK REF="STD-Huang-2005-A" TYPE="STUDY">Huang 2005 A</LINK> and <LINK REF="STD-Huang-2005-B" TYPE="STUDY">Huang 2005 B</LINK>, respectively. As we had no evidence to suggest that the envelopes were appropriately numbered in a sequential manner, random allocation could have been undermined. Two trials were described as double-blind (<LINK REF="STD-Falconer-1992" TYPE="STUDY">Falconer 1992</LINK>, <LINK REF="STD-_x00d6_zg_x00f6_nenel-2009" TYPE="STUDY">Özgönenel 2009</LINK>). Three trials used sham interventions, using identical devices in experimental and control groups (<LINK REF="STD-Falconer-1992" TYPE="STUDY">Falconer 1992</LINK>, <LINK REF="STD-Huang-2005-B" TYPE="STUDY">Huang 2005 B</LINK>, <LINK REF="STD-_x00d6_zg_x00f6_nenel-2009" TYPE="STUDY">Özgönenel 2009</LINK>). In <LINK REF="STD-Falconer-1992" TYPE="STUDY">Falconer 1992</LINK>, the sham device was fully functional, dials were lit, audible beeps were given, but no energy was delivered to the tissue. In <LINK REF="STD-Huang-2005-B" TYPE="STUDY">Huang 2005 B</LINK>, the investigators stated that the absence of a warm or stinging sensation in the control group resulted in a failure of patient blinding. <LINK REF="STD-_x00d6_zg_x00f6_nenel-2009" TYPE="STUDY">Özgönenel 2009</LINK> stated that the probe was disconnected on the back of a working ultrasound machine and the patient was unable to determine whether the cable was disconnected or not. Only the sham device used in <LINK REF="STD-Falconer-1992" TYPE="STUDY">Falconer 1992</LINK> and <LINK REF="STD-_x00d6_zg_x00f6_nenel-2009" TYPE="STUDY">Özgönenel 2009</LINK> 2009 were therefore considered to have adequate patient blinding. None of the trials was considered to have performed an intention-to-treat analysis for any of the primary outcomes of this review. Exclusions had explicitly occurred in all but two trials, with percentages of exclusions ranging from 0% to 10% in experimental groups and from 0% to 17% in control groups. In two trials (<LINK REF="STD-Cetin-2008" TYPE="STUDY">Cetin 2008</LINK>; <LINK REF="STD-_x00d6_zg_x00f6_nenel-2009" TYPE="STUDY">Özgönenel 2009</LINK>) it was unclear whether exclusions from the analysis had occurred. Three trials explicitly specified primary outcomes, although it was unclear whether these were specified a priori (<LINK REF="STD-Falconer-1992" TYPE="STUDY">Falconer 1992</LINK>; <LINK REF="STD-Huang-2005-B" TYPE="STUDY">Huang 2005 B</LINK>; <LINK REF="STD-_x00d6_zg_x00f6_nenel-2009" TYPE="STUDY">Özgönenel 2009</LINK>). Only <LINK REF="STD-Falconer-1992" TYPE="STUDY">Falconer 1992</LINK> and <LINK REF="STD-_x00d6_zg_x00f6_nenel-2009" TYPE="STUDY">Özgönenel 2009</LINK> reported a sample size calculation. None of the trials had a sample size of approximately 200 patients to achieve sufficient power for detecting a small to moderate SMD. Three trials were supported by a non-profit organisation (<LINK REF="STD-Falconer-1992" TYPE="STUDY">Falconer 1992</LINK>; <LINK REF="STD-Huang-2005-A" TYPE="STUDY">Huang 2005 A</LINK>; <LINK REF="STD-Huang-2005-B" TYPE="STUDY">Huang 2005 B</LINK>), one was also supported by a commercial body (<LINK REF="STD-Huang-2005-B" TYPE="STUDY">Huang 2005 B</LINK>). The source of funding was unclear in the the other two trials (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
<P>For the effectiveness outcomes pain and function, the quality of the evidence (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>) was classified as low in view of the risk of bias in the included, predominantly small trials of questionable quality, the large heterogeneity between trials on function, the potential for selective reporting of function outcomes and the possible indirectness of one trial (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). For the safety outcomes, the quality of the evidence (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>) was classified as low, again because of the predominantly small trials of questionable quality, the small number of trials reporting the outcomes and the absence of events resulting in not estimable relative risks.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-11-11 17:04:59 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Pain</HEADING>
<P>Five trials (320 patients, 464 knees) contributed to the meta-analysis of pain outcomes (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). The analysis suggested a SMD of -0.49 (95% CI -0.76 to -0.23), which corresponds to a difference in pain scores of 1.2 cm on a 10-cm VAS between ultrasound and control. Referring to a median pain intensity of 6.1 cm in placebo groups at baseline, this corresponds to a difference of 21% improvement (95% CI 10% to 32%) between electrostimulation and control (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). The NNT to cause one additional treatment response on pain as compared to control was 6 (95% CI 5 to 12). An I<SUP>2</SUP> of 26% indicated a low degree of of between-trial heterogeneity (P value for heterogeneity = 0.25). The funnel plot did not appear asymmetrical (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>, P value for asymmetry = 0.23).</P>
<P>
<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> presents results from stratified analyses. There was little evidence that estimates of SMD increased with the duration of ultrasound therapy applied per session (P value for trend = 0.15). There was no evidence to suggest that SMDs depended on the type of ultrasound therapy used (P value for interaction = 0.48). SMDs did not seem to depend on type of control intervention, patient blinding, total number of sessions or treatment duration. The absence of sufficient (high quality) trials hampered the exploration of associations of SMDs with other trial characteristics. In all trials it was unclear whether the provision of analgesic co-interventions was similar between groups, none had used adequate concealment of allocation, performed analyses according to the intention-to-treat principle or achieved a sample size of at least 200 patients. Therefore, we could not evaluate the impact of these characteristics.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Function</HEADING>
<P>Four trials (251 patients) contributed to the meta-analyses of function (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). The analysis suggested a SMD of -0.64 (95% CI -1.42 to 0.14, P value = 0.11), corresponding to a difference in function scores of 1.3 units on a standardised WOMAC disability scale ranging from 0 to 10, favouring ultrasound therapy. Referring to a median function score of 5.6 units in placebo groups at baseline, this corresponds to a difference of 25% improvement (95% CI -5% to 54%) between electrostimulation and control (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). The NNT to cause one additional treatment response on function as compared to control was not calculated as differences were not statistically significant. An I<SUP>2</SUP> of 88% indicated a large degree of between-trial heterogeneity (P value for heterogeneity &lt; 0.001). On visual inspection, the variation could be explained by the trial of <LINK REF="STD-Cetin-2008" TYPE="STUDY">Cetin 2008</LINK> that estimated an effect size favouring control, in contrast to the other trials. The trial by <LINK REF="STD-Huang-2005-A" TYPE="STUDY">Huang 2005 A</LINK> reported an unrealistically large effect in favour of ultrasound therapy. The funnel plot did not appear asymmetrical (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>, P value for asymmetry = 0.93).</P>
<P>
<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> presents results from stratified analyses. There was little evidence that estimates of SMD increased with the duration of ultrasound therapy applied per session (P value for trend = 0.16), but a positive interaction test suggested that SMDs were associated with the type of ultrasound therapy used, with more favourable effects of pulsed ultrasound therapy (P value for interaction = 0.005).The absence of sufficient high quality trials hampered the exploration of potential effects of all other treatment and design characteristics. Confidence intervals were either wide and tests of interaction not significant or the impact of several characteristics could not be evaluated at all.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Safety</HEADING>
<P>One trial contributed to the analysis of patients experiencing any adverse event or being withdrawn or dropping out because of adverse events (<LINK REF="STD-_x00d6_zg_x00f6_nenel-2009" TYPE="STUDY">Özgönenel 2009</LINK>). This trial reported that no adverse events or withdrawals or dropouts due to adverse events had occurred, neither in the experimental nor in the control group. Therefore, relative risks could not be estimated. Two trials (136 patients) contributed to the meta-analysis of patients experiencing any serious adverse event (<LINK REF="STD-Falconer-1992" TYPE="STUDY">Falconer 1992</LINK>; <LINK REF="STD-_x00d6_zg_x00f6_nenel-2009" TYPE="STUDY">Özgönenel 2009</LINK>). Again, the relative risk could not be calculated since both reports stated that no serious adverse events had occurred, neither in the ultrasound nor in the control group. In general, there was no evidence to suggest that electrostimulation is unsafe.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-11-11 16:45:09 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2009-10-12 04:57:50 -0400" MODIFIED_BY="[Empty name]">
<P>Our systematic review of trials comparing any type of therapeutic ultrasound with a sham or non-intervention control revealed a lack of adequately sized, methodologically sound and appropriately reported trials and a high degree of between trial heterogeneity for one of the two main outcomes, which made the interpretation of results difficult. Overall effect sizes for pain relief and improvement of function in patients with knee osteoarthritis seemed moderately in favour of ultrasound therapy. Only two trials reported safety outcomes; generally, there is no evidence to suggest that ultrasound therapy is unsafe. In view of its mechanisms of action, ultrasound therapy is rather unlikely to cause serious adverse events but active surveillance of harms with formal monitoring of potential adverse events is clearly desirable.</P>
</SUMMARY_OF_RESULTS>
<QUALITY_OF_EVIDENCE MODIFIED="2009-10-12 04:59:24 -0400" MODIFIED_BY="[Empty name]">
<P>The methodological quality and the quality of reporting was poor. All trials were small sized, including 82 patients at most. None of the trials described generation of allocation sequences or concealment of allocation, or reported whether primary outcomes were specified a priori. None of the trials was analysed according to the intention-to-treat principle, and only one trial described the occurrence of adverse events or withdrawals and dropouts because of adverse events.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2009-11-11 16:41:55 -0500" MODIFIED_BY="[Empty name]">
<P>Our review is based on a broad literature search, and it seems unlikely that we missed relevant trials (<LINK REF="REF-Egger-2003" TYPE="REFERENCE">Egger 2003</LINK>). Trial selection and data extraction, including quality assessment, were done independently by two authors to minimize bias, transcription errors and other sources of observer variation (<LINK REF="REF-Egger-2001" TYPE="REFERENCE">Egger 2001</LINK>; <LINK REF="REF-Tendal-2009" TYPE="REFERENCE">Tendal 2009</LINK>). Components used for quality assessment are validated and reported to be associated with bias (<LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>; <LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>). As with any systematic review, our study is limited by the quality of included trials. As indicated above, trials generally suffered from poor methodological quality, inadequate reporting and small sample size. The low number of trials hampered our exploration of the potential effects of ultrasound modalities, suboptimal design choices and type of funding. One trial showed an unrealistically large SMD for function (<LINK REF="STD-Huang-2005-A" TYPE="STUDY">Huang 2005 A</LINK>). Conversely, <LINK REF="STD-Cetin-2008" TYPE="STUDY">Cetin 2008</LINK> reported a null effect for pain and a trend towards a harmful effect of ultrasound for function. The confidence intervals of this trial's effect size for pain overlapped with the confidence intervals of all other trials, accordingly the estimated heterogeneity between trials was low. SMDs for function were discrepant, however: whereas the effect size in <LINK REF="STD-_x00d6_zg_x00f6_nenel-2009" TYPE="STUDY">Özgönenel 2009</LINK> were just about compatible with <LINK REF="STD-Cetin-2008" TYPE="STUDY">Cetin 2008</LINK>, and <LINK REF="STD-Huang-2005-B" TYPE="STUDY">Huang 2005 B</LINK>, they were clearly incompatible with <LINK REF="STD-Huang-2005-A" TYPE="STUDY">Huang 2005 A</LINK>. These discrepancies may be due to differences in characteristics of the intervention, differences in patient characteristics, bias or chance. The discrepancies are unlikely to be explained by the type of scale used, however: the Lequesne algofunctional scale used by Cetin 2008 was also used in <LINK REF="STD-Huang-2005-A" TYPE="STUDY">Huang 2005 A</LINK> and <LINK REF="STD-Huang-2005-B" TYPE="STUDY">Huang 2005 B</LINK>, which showed a clearcut benefit of ultrasound. If we had used walking speed data rather than the Lequesne index as a measure of function, effect sizes in the trials by Huang and colleagues would have been even more extreme in favour of ultrasound (SMD -1.7, 95% CI -2.3 to -1.1 in <LINK REF="STD-Huang-2005-A" TYPE="STUDY">Huang 2005 A</LINK> and -2.1, 95% CI -2.64 to -1.50 in <LINK REF="STD-Huang-2005-B" TYPE="STUDY">Huang 2005 B</LINK>). Walking speed was also recorded in <LINK REF="STD-Falconer-1992" TYPE="STUDY">Falconer 1992</LINK>, and although we were unable to obtain sufficient data to calculate the SMD for function, the reported results indicate that differences between groups were likely to be small, non-significant and in contrast to Huang and colleagues' results. The absence of significance can not be explained by sample size alone, as the number of patients in <LINK REF="STD-Falconer-1992" TYPE="STUDY">Falconer 1992</LINK> exceeded the numbers analysed in <LINK REF="STD-Huang-2005-A" TYPE="STUDY">Huang 2005 A</LINK>.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2009-11-11 16:45:09 -0500" MODIFIED_BY="[Empty name]">
<P>We are aware of 14 related reviews addressing the effectiveness of ultrasound therapy for knee or hip osteoarthritis (list available on request). Here we will focus mainly on the similarities with and differences to the previous version of this review (<LINK REF="REF-Welch-2001" TYPE="REFERENCE">Welch 2001</LINK>), which included three studies. We updated the search and used stricter selection criteria, which resulted in four additional trials. In contrast to the review of <LINK REF="REF-Welch-2001" TYPE="REFERENCE">Welch 2001</LINK>, we only included randomised trials. Welch and colleagues also included other design types and allowed active treatment in the control group. Here we focused on sham or non-intervention controls and excluded two previously included studies (<LINK REF="STD-Bansil-1975" TYPE="STUDY">Bansil 1975</LINK>; <LINK REF="STD-Svarcova-1988" TYPE="STUDY">Svarcova 1988</LINK>). In this update, we performed a detailed quality assessment of component trials, followed by an exploration of sources of variation between trials, including concealment of allocation, blinding, intention-to-treat analysis, and characteristics of ultrasound therapy, which was not possible in the previous version, due to the low number of trials identified. To analyse continuous data, Welch and colleagues used weighted mean differences of the change from baseline scores, whereas we used SMDs of end of treatment scores. In addition, fixed effect models were used in the previous version unless there was statistically significant heterogeneity between trials based on &#967;<SUP>2</SUP> testing. Model selection based on the mechanistic application of heterogeneity tests should be avoided, however. Here, we used random effects models, which will generally be more conservative in terms of the estimated precision, but will be more affected by small study effects than a fixed effect model, which makes an exploration of sources of variation including different types of bias mandatory. Results from the previous and current version are therefore not directly comparable. <LINK REF="REF-Welch-2001" TYPE="REFERENCE">Welch 2001</LINK> concluded that ultrasound therapy appeared to have no benefit over placebo or short wave diathermy for people with hip or knee OA. Our overall estimates for pain and function seemed moderate, favouring therapeutic ultrasound, but we share concerns expressed by <LINK REF="REF-Welch-2001" TYPE="REFERENCE">Welch 2001</LINK>, who stated that conclusions were limited by the poor reporting of the characteristics of the device, the population, the stage of OA, therapeutic application of the ultrasound and overall low methodological quality of the trials included.</P>
<P>
<LINK REF="REF-Srbely-2008" TYPE="REFERENCE">Srbely 2008</LINK> recently published a systematic review evaluating therapeutic ultrasound in people with osteoarthritis. They included five reviews and nine original studies, including animal and non randomised studies, and refrained from statistically summarising the data. Nevertheless, the paper seems to give a complete overview on the available evidence for therapeutic ultrasound. As in the present review, the authors acknowledged the low quality of evidence. They highlighted, however, that "there is an accumulating body of research suggesting that ultrasound may have the potential to provide significant benefits in the treatment and management of the osteoarthritic complex". Following this statements, we think ultrasound should not be discarded as treatment adjunctive, however, health specialist should be aware of the lack of sound evidence and be reluctant to give ultrasound therapy as a routine option, until valid evidence supporting its use becomes available.</P>
<P>Our ratings of methodological quality differ in some respect from those that can be found in PEDro (http://www.pedro.org.au/). As an example, for both trials of <LINK REF="STD-Huang-2005-A" TYPE="STUDY">Huang 2005 A</LINK> and <LINK REF="STD-Huang-2005-B" TYPE="STUDY">Huang 2005 B</LINK> our ratings concerning generation of allocation sequences and concealment of allocation differ. We rated these components as unclear, whereas PEDro assessors rated them as adequate. This difference can not be explained by the definitions used, which are similar in our review and in PEDro. PEDro does not allow for a category unclear, however, which may have driven the assessors to give credit to these two trials and classify randomisation methods as adequate rather than inadequate in the absence of evidence suggesting neither of the two mutually exclusive categories.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-11-11 16:46:42 -0500" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-10-12 05:07:21 -0400" MODIFIED_BY="[Empty name]">
<P>Despite the widespread use of therapeutic ultrasound in physical therapy, evidence of its clinical effectiveness in people with hip or knee OA is of poor quality and therefore inconclusive. The effects of ultrasound therapy on both, knee pain and function, are potentially clinically relevant and deserve further clinical evaluation.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-11-11 16:46:42 -0500" MODIFIED_BY="[Empty name]">
<P>The current systematic review is inconclusive, hampered by the inclusion of only small trials of questionable quality. Adequately sized randomised parallel-group trials in approximately 2 x 100 patients with knee or hip osteoarthritis are necessary to determine whether either continuous or pulsed ultrasound therapy is indeed associated with a clinically relevant benefit on pain and function. A sample size of 2 x 100 patients will yield more than 80% power to detect a small to moderate SMD of -0.40 at a two-sided P value of 0.05. The trials should enrol patients without prior experience of ultrasound therapy or evaluate success of blinding at the end of trial, use adequate concealment of allocation, experimental and sham interventions that are close to indistinguishable and an intention-to-treat analysis. Evaluation whether effects increase with longer stimulation times per session or with type of ultrasound is recommended.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-11-11 02:33:25 -0500" MODIFIED_BY="[Empty name]">
<P>Vivian Welch, Lucie Brosseau, Joan Peterson, Beverley Shea, Peter Tugwell and George A. Wells were authors on the original review. We thank the Cochrane Musculoskeletal editorial team for valuable comments and Malcolm Sturdy for database support. The authors are grateful to Judith Falconer for providing additional information concerning design and for trying to locate files of her trial published in 1992. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-02-18 06:23:46 -0500" MODIFIED_BY="[Empty name]">
<P>None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-10-12 05:08:02 -0400" MODIFIED_BY="[Empty name]">
<P>Study conception: Rutjes, Jüni<BR/>Protocol development: Rutjes, Nüesch, Jüni<BR/>Acquisition of data: Rutjes, Nüesch, Sterchi<BR/>Analysis and interpretation of data: Rutjes, Nüesch, Jüni<BR/>Drafting of the manuscript: Rutjes, Jüni<BR/>Critical revision of the manuscript for important intellectual content:: Rutjes, Nüesch, Sterchi, Jüni<BR/>Statistical analysis. Nüesch, Rutjes, Jüni<BR/>Obtained funding: Jüni</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-10-12 05:08:56 -0400" MODIFIED_BY="[Empty name]">
<P>Before embarking on this review, we generated a standard protocol for this, and all other Cochrane reviews performed by our group. The protocol was approved by the Editorial Board of the Cochrane Musculoskeletal Review Group (CMSG), but, as an update, did not result in a specific publication in the Cochrane database. Because of the low number of trials identified, we deviated from the standard protocol in terms of omitting several stratified analyses and univariable random-effects meta-regression analyses to determine whether treatment effects were affected by treatment or design characteristics. In addition, we used risk of bias tables to present the methodological quality of included trials and a summary of findings table to present results.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-11-11 16:54:13 -0500" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-10-12 03:26:06 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-10-12 03:26:06 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Cetin-2008" MODIFIED="2009-02-19 11:09:24 -0500" MODIFIED_BY="[Empty name]" NAME="Cetin 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-02-19 11:08:34 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cetin N, Aytar A, Atalay A, Akman MN</AU>
<TI>Comparing hot pack, short-wave diathermy, ultrasound, and TENS on isokinetic strength, pain, and functional status of women with osteoarthritic knees: a single-blind, randomized, controlled trial</TI>
<SO>American Journal of Physical Medicine &amp; Rehabilitation</SO>
<YR>2008</YR>
<VL>87</VL>
<PG>443-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Falconer-1992" NAME="Falconer 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Falconer J, Hayes KW, Change RW</AU>
<TI>Effect of ultrasound on mobility in osteoarthritis of the knee</TI>
<SO>Arthritis Care and Research</SO>
<YR>1992</YR>
<VL>5</VL>
<NO>1</NO>
<PG>29-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2005-A" MODIFIED="2009-10-12 03:25:50 -0400" MODIFIED_BY="[Empty name]" NAME="Huang 2005 A" YEAR="2005">
<REFERENCE MODIFIED="2009-10-12 03:25:50 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang MH, Yang RC, Lee CL, Chen TW, Wang MC, Huang MH, et al</AU>
<TI>Preliminary results of integrated therapy for patients with knee osteoarthritis</TI>
<SO>Arthritis and rheumatism</SO>
<YR>2005</YR>
<VL>53</VL>
<PG>812-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2005-B" MODIFIED="2009-10-12 03:26:06 -0400" MODIFIED_BY="[Empty name]" NAME="Huang 2005 B" YEAR="">
<REFERENCE MODIFIED="2009-10-12 03:26:06 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang MH, Lin YS, Lee CL, Yang RC, Huang MH, Lin YS, et al</AU>
<TI>Use of ultrasound to increase effectiveness of isokinetic exercise for knee osteoarthritis</TI>
<SO>Archives of Physical Medicine &amp; Rehabilitation</SO>
<YR>2005</YR>
<VL>86</VL>
<PG>1545-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x00d6_zg_x00f6_nenel-2009" MODIFIED="2009-07-22 05:18:01 -0400" MODIFIED_BY="[Empty name]" NAME="Özgönenel 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-07-22 05:18:01 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Özgönenel L, Aytekin E, Durmu&#351;o&#287;lu G</AU>
<TI>A double-blind trial of clinical effects of therapeutic ultrasound in knee osteoarthritis</TI>
<SO>Ultrasound in medicine &amp; biology</SO>
<YR>2009</YR>
<VL>35</VL>
<NO>1</NO>
<PG>44-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-07-22 05:20:05 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Antich-1986" MODIFIED="2009-02-18 10:49:02 -0500" MODIFIED_BY="[Empty name]" NAME="Antich 1986" YEAR="1986">
<REFERENCE MODIFIED="2009-02-18 10:49:02 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Antich TJ, Randall CC, Westbrook RA, Morrissey MC, Brewster CE</AU>
<TI>Physical therapy treatment of knee extensor mechanism disorders: comparison of four treatment modalities</TI>
<SO>The Journal of Orthopaedic and Sports Physical Therapy</SO>
<YR>1986</YR>
<VL>8</VL>
<PG>255-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bansil-1975" MODIFIED="2009-07-22 05:20:05 -0400" MODIFIED_BY="[Empty name]" NAME="Bansil 1975" YEAR="1975">
<REFERENCE MODIFIED="2009-07-22 05:20:05 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bansil CK, Joshi JB</AU>
<TI>Effectiveness of shortwave diathermy and ultrasound in the treatment of osteoarthritis of the knee joint</TI>
<SO>Medical journal of Zambia</SO>
<YR>1975</YR>
<VL>9</VL>
<NO>5</NO>
<PG>138-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Esmat-1975" MODIFIED="2009-02-18 11:38:13 -0500" MODIFIED_BY="[Empty name]" NAME="Esmat 1975" YEAR="1975">
<REFERENCE MODIFIED="2009-02-18 11:38:13 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Esmat N</AU>
<TI>Treatment of arthrosis deformans by simultaneous application of interferential current and ultrasonic waves</TI>
<SO>The Journal of the Egyptian Medical Association</SO>
<YR>1975</YR>
<VL>58</VL>
<PG>328-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jan-1991" MODIFIED="2009-02-18 11:28:55 -0500" MODIFIED_BY="[Empty name]" NAME="Jan 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-02-18 11:28:55 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jan MH, Lai JS</AU>
<TI>The effects of physiotherapy on osteoarthritic knees of females</TI>
<SO>Journal Formosan Medical Association</SO>
<YR>1991</YR>
<VL>90</VL>
<PG>1008-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-2004" MODIFIED="2009-02-18 07:44:41 -0500" MODIFIED_BY="[Empty name]" NAME="Jones 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-02-18 07:44:41 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jones JP, Bae YK</AU>
<TI>Ultrasonic imaging, characterization, and stimulation of acupuncture points</TI>
<SO>Journal of Alternative &amp; Complementary Medicine</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>1</NO>
<PG>202-203 (O-9)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindahl-1952" MODIFIED="2009-02-20 09:45:11 -0500" MODIFIED_BY="[Empty name]" NAME="Lindahl 1952" YEAR="1952">
<REFERENCE MODIFIED="2009-02-20 09:45:11 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindahl O</AU>
<TI>Clinical effect of ultrasonic waves in chondromalacic and osteoarthritic changes in the knee</TI>
<SO>Rheumatism</SO>
<YR>1952</YR>
<VL>8</VL>
<NO>2</NO>
<PG>36-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Machalett-1975" MODIFIED="2009-02-18 11:56:13 -0500" MODIFIED_BY="[Empty name]" NAME="Machalett 1975" YEAR="1975">
<REFERENCE MODIFIED="2009-02-18 11:56:13 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Machalett H</AU>
<TI>Questions of therapy and morbidity of the bony framework and the locomotor apparatus in a rural practice</TI>
<SO>Zeitschrift für ärztliche Fortbildung</SO>
<YR>1975</YR>
<VL>69</VL>
<PG>43-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svarcova-1988" MODIFIED="2009-07-22 05:19:20 -0400" MODIFIED_BY="[Empty name]" NAME="Svarcova 1988" YEAR="1988">
<REFERENCE MODIFIED="2009-07-22 05:19:20 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svarcova J, Trnavsky K, Zvarova J</AU>
<TI>The influence of ultrasound, galvanic currents and shortwave diathermy on pain intensity in patients with osteoarthritis</TI>
<SO>Scandinavian journal of rheumatology</SO>
<YR>1988</YR>
<VL>Suppl. 67</VL>
<PG>83-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zielke-1987" MODIFIED="2009-02-18 12:19:51 -0500" MODIFIED_BY="[Empty name]" NAME="Zielke 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-02-18 12:19:51 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zielke A</AU>
<TI>Physical therapy in degenerative diseases of the joints</TI>
<SO>Zeitschrift für die gesamte innere Medizin und ihre Grenzgebiete</SO>
<YR>1987</YR>
<VL>42</VL>
<PG>105-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-02-18 16:55:30 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Kostadinov-1978" MODIFIED="2009-02-18 16:55:30 -0500" MODIFIED_BY="[Empty name]" NAME="Kostadinov 1978" YEAR="1978">
<REFERENCE MODIFIED="2009-02-18 16:54:56 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kostadinov D, Mihailov S, Kalaidjiev G. Kurortologiya i</AU>
<TI>Comparative investigations on gonarthrosis treatment with some physical factors. [Bulgarian]</TI>
<SO>Fizioterapiya</SO>
<YR>1978</YR>
<VL>15</VL>
<PG>169-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-11-11 16:54:13 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-11-11 16:54:13 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" MODIFIED="2009-02-18 06:44:36 -0500" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman R, Brandt K, Hochberg M, Moskowitz R, Bellamy N, Bloch DA, et al</AU>
<TI>Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop</TI>
<SO>Osteoarthritis Cartilage</SO>
<YR>1996</YR>
<VL>4</VL>
<NO>4</NO>
<PG>217-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bellamy-1995" MODIFIED="2009-07-22 07:04:31 -0400" MODIFIED_BY="[Empty name]" NAME="Bellamy 1995" TYPE="JOURNAL_ARTICLE">
<AU>Bellamy N</AU>
<TI>Outcome measurement in osteoarthritis clinical trials</TI>
<SO>J Rheumatol</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>suppl.43</NO>
<PG>49-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chinn-2000" MODIFIED="2009-07-22 07:04:31 -0400" MODIFIED_BY="[Empty name]" NAME="Chinn 2000" TYPE="JOURNAL_ARTICLE">
<AU>Chinn S</AU>
<TI>A simple method for converting an odds ratio to effect size for use in meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>22</NO>
<PG>3127-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clegg-2006" MODIFIED="2009-07-22 07:04:31 -0400" MODIFIED_BY="[Empty name]" NAME="Clegg 2006" TYPE="JOURNAL_ARTICLE">
<AU>Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al</AU>
<TI>Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>354</VL>
<NO>8</NO>
<PG>795-808</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen_x002c_-1988" MODIFIED="2009-02-18 06:44:36 -0500" MODIFIED_BY="[Empty name]" NAME="Cohen, 1988" TYPE="BOOK">
<AU>Cohen, J. (1988)</AU>
<SO>Statistical power analysis for the behavioral sciences</SO>
<YR>1988</YR>
<EN>2nd</EN>
<PB>Lawrence Earlbaum Associates</PB>
<CY>Hillsdale, NJ</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dafinova-1996" MODIFIED="2009-02-20 05:27:47 -0500" MODIFIED_BY="[Empty name]" NAME="Dafinova 1996" TYPE="JOURNAL_ARTICLE">
<AU>Dafinova Y, Boncheva I, Dikova M, Popov V, Lozanova M</AU>
<TI>Ultraphonophoretic application of voltaren emulgel in patients with knee-joint osteoarthrosis [Bulgarian]</TI>
<SO>Fizikalna Kurortna i Rekhabilitatsionna Meditsina</SO>
<YR>1996</YR>
<VL>35</VL>
<NO>1</NO>
<PG>18-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2009-02-18 06:44:36 -0500" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled clinical trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS MODIFIED="2009-02-18 06:42:45 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="3802833"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" MODIFIED="2009-08-07 05:47:25 -0400" MODIFIED_BY="[Empty name]" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6964</NO>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dincer-2008" MODIFIED="2009-02-20 05:21:58 -0500" MODIFIED_BY="[Empty name]" NAME="Dincer 2008" TYPE="JOURNAL_ARTICLE">
<AU>Dincer U, Cakar E, Ozdemir B, Kiralp MZ, Dursun H</AU>
<TI>Comparison of effects of combined physical therapy program and exercise on corrupted balance functions in patient with knee bilateral osteoarthritis [Turkish]</TI>
<SO>Romatizma</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>1</NO>
<PG>9-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-2001" MODIFIED="2009-02-20 09:40:47 -0500" MODIFIED_BY="[Empty name]" NAME="Egger 2001" TYPE="BOOK_SECTION">
<AU>Egger M, Smith GD</AU>
<TI>Principles of and procedures for systematic reviews</TI>
<SO>Systematic Reviews in Health Care: Meta-Analyis in Context</SO>
<YR>2001</YR>
<PG>23-42</PG>
<ED>Egger M, Smith GD, Altman DG</ED>
<PB>BMJ Books</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-2003" MODIFIED="2009-02-20 09:42:20 -0500" MODIFIED_BY="[Empty name]" NAME="Egger 2003" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Juni P, Bartlett C, Holenstein F, Sterne J</AU>
<TI>How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study</TI>
<SO>Health technology assessment (Winchester, England)</SO>
<YR>2003</YR>
<VL>7</VL>
<NO>1</NO>
<PG>1-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2009-07-22 07:04:31 -0400" MODIFIED_BY="[Empty name]" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hartley-1993" MODIFIED="2009-02-20 10:23:18 -0500" MODIFIED_BY="[Empty name]" NAME="Hartley 1993" TYPE="BOOK">
<AU>Hartley A</AU>
<TI>Therapeutic Ultrasound</TI>
<SO>Anne Hartley Agency</SO>
<YR>1993</YR>
<EN>2</EN>
<PB>Anne Hartley Agency</PB>
<CY>Etobicoke, Ontario, Canada</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hicks-1990" MODIFIED="2009-08-07 05:47:35 -0400" MODIFIED_BY="[Empty name]" NAME="Hicks 1990" TYPE="JOURNAL_ARTICLE">
<AU>Hicks JE</AU>
<TI>Exercise in patients with inflammatory arthritis and connective tissue disease</TI>
<SO>Rheumatic diseases clinics of North America</SO>
<YR>1990</YR>
<VL>16</VL>
<NO>4</NO>
<PG>845-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2009-02-18 06:44:36 -0500" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-10-10 07:18:54 -0400" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="BOOK">
<AU>Higgins JPT, Green S (eds)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008. Available from www.cochrane-handbook.org</YR>
<EN>Version 5.0.1 [updated September 2008]</EN>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2001" MODIFIED="2009-10-09 10:48:00 -0400" MODIFIED_BY="[Empty name]" NAME="Jüni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: Assessing the quality of controlled clinical trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7303</NO>
<PG>42-6</PG>
<IDENTIFIERS MODIFIED="2009-02-18 06:42:45 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="11440947"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2006" MODIFIED="2009-02-18 06:44:36 -0500" MODIFIED_BY="[Empty name]" NAME="Jüni 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Reichenbach S, Dieppe P</AU>
<TI>Osteoarthritis: rational approach to treating the individual</TI>
<SO>Best practice &amp; research. Clinical rheumatology</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>4</NO>
<PG>721-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kalpakcioglu-2006" MODIFIED="2009-02-20 05:32:48 -0500" MODIFIED_BY="[Empty name]" NAME="Kalpakcioglu 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kalpakcioglu BA, Cakmak B, Bahadir C</AU>
<TI>Comparison of ultrasound and short wave diathermy therapy in knee osteoarthritis [Turkish]</TI>
<SO>Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi</SO>
<YR>2006</YR>
<VL>52</VL>
<NO>4</NO>
<PG>168-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kozanoglu-2003" MODIFIED="2009-02-20 10:25:41 -0500" MODIFIED_BY="[Empty name]" NAME="Kozanoglu 2003" TYPE="JOURNAL_ARTICLE">
<AU>Kozanoglu E, Basaran S, Guzel R, Guler-Uysal F</AU>
<TI>Short term efficacy of ibuprofen phonophoresis versus continuous ultrasound therapy in knee osteoarthritis</TI>
<SO>Swiss Medical Weekly</SO>
<YR>2003</YR>
<VL>133</VL>
<PG>333-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelson-1999" NAME="Nelson 1999" TYPE="BOOK">
<AU>Nelson RM, Hayes KW, Currier DP</AU>
<SO>Clinical Electrotherapy</SO>
<YR>1999</YR>
<EN>Third</EN>
<PB>Appleton &amp; Rouge</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-N_x00fc_esch-2009" MODIFIED="2009-10-09 10:47:28 -0400" MODIFIED_BY="[Empty name]" NAME="Nüesch 2009" TYPE="JOURNAL_ARTICLE">
<AU>Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Bürgi E, Scherer M, et al</AU>
<TI>The effects of the exclusion of patients from the analysis in randomised controlled trials: meta-epidemiological study</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>339</VL>
<PG>b3244</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ones-2006" MODIFIED="2009-02-20 05:16:25 -0500" MODIFIED_BY="[Empty name]" NAME="Ones 2006" TYPE="JOURNAL_ARTICLE">
<AU>Ones K, Tetik S, Tetik C, Ones N</AU>
<TI>The effects of heat on osteoarthritis of the knee</TI>
<SO>The Pain Clinic</SO>
<YR>2006</YR>
<VL>18</VL>
<NO>1</NO>
<PG>67-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pham-2004" MODIFIED="2009-02-18 06:44:36 -0500" MODIFIED_BY="[Empty name]" NAME="Pham 2004" TYPE="JOURNAL_ARTICLE">
<AU>Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, et al</AU>
<TI>OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited</TI>
<SO>Osteoarthritis Cartilage</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>5</NO>
<PG>389-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Qin-2008" MODIFIED="2009-07-24 06:52:26 -0400" MODIFIED_BY="[Empty name]" NAME="Qin 2008" TYPE="JOURNAL_ARTICLE">
<AU>Qin XY, Li XX, Berghea F, Suteanu S, Qin X-Y, Li X-X, et al</AU>
<TI>Comparative study on Chinese medicine and western medicine for treatment of osteoarthritis of the knee in Caucasian patients</TI>
<SO>Zhongguo Zhenjiu</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>6</NO>
<PG>459-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rand-2007" MODIFIED="2009-02-18 06:36:09 -0500" MODIFIED_BY="[Empty name]" NAME="Rand 2007" TYPE="JOURNAL_ARTICLE">
<AU>Rand SE, Goerlich C, Marchand K, Jablecki N</AU>
<TI>The physical therapy prescription</TI>
<SO>American family physician</SO>
<YR>2007</YR>
<VL>76</VL>
<NO>11</NO>
<PG>1661-6</PG>
<IDENTIFIERS MODIFIED="2009-02-18 06:36:04 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="18092708"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Reichenbach-2007" MODIFIED="2009-10-09 10:45:29 -0400" MODIFIED_BY="[Empty name]" NAME="Reichenbach 2007" TYPE="JOURNAL_ARTICLE">
<AU>Reichenbach S, Sterchi R, Scherer M, Trelle S, Bürgi E, Bürgi U, et al</AU>
<TI>Meta-analysis: chondroitin for osteoarthritis of the knee or hip</TI>
<SO>Annals of internal medicine</SO>
<YR>2007</YR>
<VL>146</VL>
<NO>8</NO>
<PG>580-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-R_x00fc_cker-2008" MODIFIED="2009-11-11 16:54:13 -0500" MODIFIED_BY="[Empty name]" NAME="Rücker 2008" TYPE="JOURNAL_ARTICLE">
<AU>Rücker G, Schwarzer G, Carpenter JR, Schumacher M</AU>
<TI>Undue reliance on I<SUP>2</SUP> in assessing heterogeneity may mislead</TI>
<SO>BMC medical research methodology</SO>
<YR>2008</YR>
<VL>8</VL>
<NO>1</NO>
<PG>79</PG>
<IDENTIFIERS MODIFIED="2009-02-18 06:42:45 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19036172"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Solomon-1997" MODIFIED="2009-02-18 06:44:36 -0500" MODIFIED_BY="[Empty name]" NAME="Solomon 1997" TYPE="BOOK_SECTION">
<AU>Solomon L</AU>
<TI>Clinical features of osteoarthritis</TI>
<SO>Textbook of Rheumatology</SO>
<YR>1997</YR>
<VL>2</VL>
<PG>1383-93</PG>
<EN>5th</EN>
<ED>Kelly WN, Harris ED Jr, Ruddy S, Sledge CB</ED>
<PB>WB Saunders</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Srbely-2008" MODIFIED="2009-02-20 09:25:29 -0500" MODIFIED_BY="[Empty name]" NAME="Srbely 2008" TYPE="JOURNAL_ARTICLE">
<AU>Srbely JZ</AU>
<TI>Ultrasound in the management of osteoarthritis: part I: a review of the current literature</TI>
<SO>Journal of the Canadian Chiropractic Association</SO>
<YR>2008</YR>
<VL>52</VL>
<PG>30-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2001" MODIFIED="2009-10-12 08:21:23 -0400" MODIFIED_BY="[Empty name]" NAME="Sterne 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Egger M</AU>
<TI>Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2001</YR>
<VL>54</VL>
<NO>10</NO>
<PG>1046-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tendal-2009" MODIFIED="2009-10-10 07:18:34 -0400" MODIFIED_BY="[Empty name]" NAME="Tendal 2009" TYPE="JOURNAL_ARTICLE">
<AU>Tendal B, Higgins JP, Jüni P, Hróbjartsson A, Trelle S, Nüesch E, et al</AU>
<TI>Disagreements in meta-analyses using outcomes measured on continuous or rating scales: observer agreement study</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>339</VL>
<PG>b3128</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tuzun-2003" MODIFIED="2009-02-20 05:20:34 -0500" MODIFIED_BY="[Empty name]" NAME="Tuzun 2003" TYPE="JOURNAL_ARTICLE">
<AU>Tuzun EH, Otman S, Kirdi N</AU>
<TI>Comparison of different methods of pulsed shortwave diathermy in knee osteoarthritis</TI>
<SO>The Pain Clinic</SO>
<YR>2003</YR>
<VL>15</VL>
<PG>421-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Veenhof-2007" MODIFIED="2009-02-20 05:18:44 -0500" MODIFIED_BY="[Empty name]" NAME="Veenhof 2007" TYPE="JOURNAL_ARTICLE">
<AU>Veenhof C, Chm, Dekker J, Koke AJA, Oostendorp RA, Bijlsma JWJ</AU>
<TI>Which patients with osteoarthritis of hip and/or knee benefit most from behavioral graded activity?</TI>
<SO>International Journal of Behavioral Medicine</SO>
<YR>2007</YR>
<VL>14</VL>
<PG>86-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2009-10-09 10:46:56 -0400" MODIFIED_BY="[Empty name]" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical research ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7644</NO>
<PG>601-5</PG>
<IDENTIFIERS MODIFIED="2009-02-18 06:42:45 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="18316340"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Yang-2005" MODIFIED="2009-02-20 05:25:13 -0500" MODIFIED_BY="[Empty name]" NAME="Yang 2005" TYPE="JOURNAL_ARTICLE">
<AU>Yang DJ, Xu FY, Ma L, Gan JH</AU>
<TI>Ultrasonic wave in combination with quadriceps exercise for the treatment of senile knee osteoarthritis</TI>
<SO>Zhongguo Linchuang Kangfu [Chinese Journal of Clinical Rehabilitation]</SO>
<YR>2005</YR>
<VL>9</VL>
<PG>252-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2008" MODIFIED="2009-02-18 06:36:09 -0500" MODIFIED_BY="[Empty name]" NAME="Zhang 2008" TYPE="JOURNAL_ARTICLE">
<AU>Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al</AU>
<TI>OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines</TI>
<SO>Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society</SO>
<YR>2008</YR>
<VL>16</VL>
<NO>2</NO>
<PG>137-62</PG>
<IDENTIFIERS MODIFIED="2009-02-18 06:36:04 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="18279766"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-02-20 13:38:26 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Welch-2001" MODIFIED="2009-02-20 13:38:26 -0500" MODIFIED_BY="[Empty name]" NAME="Welch 2001" TYPE="COCHRANE_REVIEW">
<AU>Welch V, Brosseau L, Peterson J, Shea B, Tugwell P, Wells G</AU>
<TI>Therapeutic ultrasound for osteoarthritis of the knee</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2009-02-20 10:32:33 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-20 10:32:33 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003132 "/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-10-12 06:20:43 -0400" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-10-12 06:20:43 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-03-03 04:58:04 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cetin-2008">
<CHAR_METHODS MODIFIED="2009-03-03 04:58:04 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>5-arm parallel group design<BR/>Trial duration: 8 weeks <BR/>No power calculation reported<BR/>Funding by non-profit organisation: no information provided</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-20 04:57:01 -0500" MODIFIED_BY="[Empty name]">
<P>100 patients randomised*<BR/>100 patients with knee OA reported at baseline<BR/>Study joints: 100 knees<BR/>Number of females: 100 of 100 (100%)<BR/>Average age: 60 years<BR/>Average BMI: 28 kg/m2<BR/>Average disease duration: not reported<BR/>Severity**: according to Kellgren and Lawrence: 3 patiens with grade I, 16 with II, 16 with grade III, and 5 with grade IV</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-19 11:18:10 -0500" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: Ultrasound therapy + hot packs + isokinetic exercise, 3 times per week<BR/>Control intervention: hot packs + isokinetic exercise, 3 times per week<BR/>Duration of treatment period: 8 weeks<BR/>Analgesics allowed, unclear whether intake was similar between groups.</P>
<P>Device: Sonopuls 590 US (Enraf Nonius)<BR/>Type: continuous US<BR/>Duration of stimulation per session: 10 minutes, minutes per treated region not reported<BR/>Total sessions: 24<BR/>Frequency: 1.00 MHz<BR/>Intensity: 1.5 W/cm2<BR/>Head size (cm2): not reported<BR/>Treated anatomical areas: around the knee, with lower extremity in maximal extension<BR/>Area treated per session: not reported<BR/>Skin preparation: not reported (direct contact)<BR/>Safety precautions: not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-19 11:24:07 -0500" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: Pain on walking after 8 weeks (VAS), described as 'Knee pain severity after a 50-m walk'<BR/>Extracted function outcome: Lequesne OA index global score (Likert) after 8 weeks</P>
<P>No primary outcome reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-20 05:02:37 -0500" MODIFIED_BY="[Empty name]">
<P>*Only 2 arms (40 patients) qualified for inclusion in this review. In total, 100 patients were equally randomised in 5 groups: 1) short wave diathermy + hot packs + isokinetic exercise, 2) transcutaneous electrical stimulation + hot packs + isokinetic exercise, 3) Ultrasound therapy + hot packs + isokinetic exercise, 4) hot packs + isokinetic exercise, 5) isokinetic exercise.</P>
<P>** numbers applicable to the 40 patients included in the review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-12 05:09:06 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Falconer-1992">
<CHAR_METHODS MODIFIED="2009-03-03 04:58:57 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind trial<BR/>2-arm parallel group design<BR/>Trial duration: 14.6 weeks<BR/>Power calculation reported<BR/>Funding by non-profit organisation: Arthritis Foundation, Arthritis Health Prof. Association, NIAMS Grant number AM30692<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-19 11:34:53 -0500" MODIFIED_BY="[Empty name]">
<P>74 patients randomised<BR/>Number of patients with knee OA not reported at baseline<BR/>Study joints analysed: 69<BR/>Number of females: 50 of 69 (72%)<BR/>Average age: 68 years<BR/>Average BMI: not reported<BR/>Average disease duration: 6.95 years (US: 6.4, Control: 7.5)<BR/>Severity: moderate knee OA, Altman grade II, 8 patients had history of total knee replacement<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-20 11:08:00 -0500" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: ultrasound therapy, 2-3 times per week</P>
<P>Control intervention: sham ultrasound therapy, 2-3 times per week</P>
<P>Concurrent Treatment (30 minutes): passive stretch during cooling period, manual therapy, active ROM and isometric strengthening exercises, instruction in daily home exercise, joint protection.</P>
<P>Duration of treatment period: 6 weeks</P>
<P>Unclear whether analgesics were allowed and the intake was assessed</P>
<P>Device: Sonopulus 590 (Enraf Nonius)<BR/>Type: not reported, but in light of the maximal intensity reported, most likely pulsed ultrasound therapy<BR/>Duration of stimulation per session: 12 minutes, 3 minutes per treated region<BR/>Total sessions: 12<BR/>Frequency: 1.00 MHz<BR/>Intensity: mean 1,7 W/cm2, increased to maximum tolerable dosage, at which warmth without pain was felt, not exceeding 2.5 W/cm2<BR/>Head size (cm2): 10 (effective radiating surface 8.5)<BR/>Treated anatomical areas: anterior, posterior, medial, lateral, with lower extremity in maximal flexion or extension, depending on which end range presented with the most functional loss<BR/>Area treated per session: 100cm2<BR/>Skin preparation: aqueous gel<BR/>Safety precautions: power increased in 0.1W/cm2 increments to a maximum of 2.5W/cm2<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-12 05:09:06 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: Global pain at 6 weeks, described as 'pain', measured on 10 cm VAS.</P>
<P>Extracted function outcome*: Walking disability at 6 weeks, described as 'gait velocity'.</P>
<P>Primary outcome: Pain and active range of motion</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-20 08:54:07 -0500" MODIFIED_BY="[Empty name]">
<P>*not enough data presented to allow pooling, it was only stated that no significant differences were observed between the experimental and control group. Despite a great effort, Dr. Falconer was unable to locate the original data file and to provide additional data.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-12 05:09:52 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2005-A">
<CHAR_METHODS MODIFIED="2009-03-03 04:59:26 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised trial<BR/>4-arm parallel group design<BR/>Trial duration: 8 weeks<BR/>No power calculation reported<BR/>Funding by non-profit organisation: Supported by a project grant provided from the National Science Council of Taiwan</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-23 12:00:52 -0500" MODIFIED_BY="[Empty name]">
<P>140 patients randomised*<BR/>140 patients with bilateral knee OA reported at baseline<BR/>Study joints: 280 knees for pain outcome<BR/>Number of females: 113 of 140 (81%)<BR/>Average age: 65 years<BR/>Average BMI: not reported<BR/>Average disease duration: not reported, ranging from 5 months to 12 years<BR/>Severity: moderate knee OA, Altman grade II</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-20 11:08:16 -0500" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: Ultrasound therapy, isokinetic exercise, hot packs, three times per week<BR/>Control intervention: isokinetic exercise and hot packs, three times per week<BR/>Duration of treatment period: 8 weeks<BR/>Unclear whether analgesics were allowed and the intake was assessed</P>
<P>Device: Sonopulus 590 (Enraf Nonius)<BR/>Duration of stimulation per session: unclear, 5 minutes per treated to each treated region<BR/>Total sessions: 24 planned<BR/>Frequency: 1.00 MHz<BR/>Intensity: up to a level at which a warm sensation or a mild sting was felt, not exceeding 2.5 W/cm2<BR/>Head size (cm2): not reported<BR/>Treated anatomical areas: medial collateral ligament, anserine bursa, and the popliteal fossa tender points (5min/area), with lower extremity in 90º flexion for first 2 areas and maximal extension for popliteal fossa points<BR/>Area treated per session: 25cm2<BR/>Skin prep: not reported<BR/>Safety precautions: none reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-12 05:09:52 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: Pain on walking at 8 weeks, described as 'severity of knee pain while remaining in a weight-bearing position (walking or standing) for 5 minutes', measured on 10 cm VAS.</P>
<P>Extracted function outcome: Lequesne's Index after 8 weeks, measured on 0 to 26 Likert scale. </P>
<P>Primary outcome: not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-20 03:44:26 -0500" MODIFIED_BY="[Empty name]">
<P>*2 arms (70 patients) were excluded from the review: no intervention arm (35 patients) and isokinetic exercise + pulsed ultrasound + intraarticular hyaluronan + hot packs arm (35 patients).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-12 06:20:43 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2005-B">
<CHAR_METHODS MODIFIED="2009-10-12 06:20:43 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised trial<BR/>4-arm parallel group design<BR/>Trial duration: 8 weeks<BR/>No power calculation reported<BR/>Funding by non-profit organisation: Supported by a project grant provided from the National Science Council of Taiwan (grant number NSC-92-2314-B-037-067)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-23 12:00:36 -0500" MODIFIED_BY="[Empty name]">
<P>120 patients randomised*<BR/>120 patients with bilateral knee OA reported at baseline<BR/>Study joints: 240 knees for pain outcome<BR/>Number of females: 97 of 120 (81%)<BR/>Average age: 62 years<BR/>Average BMI: not reported<BR/>Average disease duration: not reported, ranging from 6 months to 11 years<BR/>Severity: moderate knee OA, Altman grade II</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-20 11:02:48 -0500" MODIFIED_BY="[Empty name]">
<P>
<I>Comparison 1: </I>
<BR/>Experimental intervention: continuous ultrasound therapy, isokinetic exercise, hot packs, three times per week<BR/>Control intervention: sham ultrasound therapy, isokinetic exercise and hot packs, three times per week</P>
<P>
<I>Comparison 2: </I>
<BR/>Experimental intervention: pulsed ultrasound therapy, isokinetic exercise, hot packs, three times per week<BR/>Control intervention: sham ultrasound therapy, isokinetic exercise and hot packs, three times per week<BR/>
</P>
<P>Duration of treatment period: 8 weeks<BR/>Unclear whether analgesics were allowed and the intake was assessed</P>
<P>Device: Sonopulus 590 (Enraf Nonius)<BR/>Duration of stimulation per session: unclear, 5 minutes per treated to each treated region<BR/>Total sessions: 24 planned<BR/>Frequency: 1.00 MHz<BR/>Intensity: up to a level at which a warm sensation or a mild sting was felt, not exceeding 2.5 W/cm2<BR/>Head size (cm2): not reported<BR/>Treated anatomical areas: medial collateral ligament, anserine bursa, and the popliteal fossa tender points (5min/area), with lower extremity in 90º flexion for first 2 areas and maximal extension for popliteal fossa points<BR/>Area treated per session: 25cm2<BR/>Skin prep: not reported<BR/>Safety precautions: none reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-12 05:11:44 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: Pain on walking at 8 weeks, described as 'severity of knee pain while remaining in a weight-bearing position (walking or standing) for 5 minutes in the parallel bars of the treadmill', measured on 10 cm VAS.</P>
<P>Extracted function outcome: Lequesne's Index after 8 weeks, measured on 0 to 26 Likert scale. </P>
<P>Primary outcome: Change in ambulation speed and Lequesne index</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-20 03:44:57 -0500" MODIFIED_BY="[Empty name]">
<P>*1 arm (30 patients), in which no intervention was given, was excluded from the review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-12 05:12:40 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x00d6_zg_x00f6_nenel-2009">
<CHAR_METHODS MODIFIED="2009-10-12 05:12:19 -0400" MODIFIED_BY="[Empty name]">
<P>Randomised trial<BR/>2-arm parallel group design<BR/>Trial duration: 2 weeks<BR/>Power calculation reported<BR/>Funding by non-profit organisation: No information provided</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-12 05:12:25 -0400" MODIFIED_BY="[Empty name]">
<P>67 patients randomised<BR/>67 patients with newly diagnosed knee OA reported at baseline<BR/>Study joints: 67 knees<BR/>Number of females: 54 of 67 (81%)<BR/>Average age: 55 years<BR/>Average BMI: 32 kg/m<SUP>2</SUP>
<BR/>Average disease duration: not reported, but all patients were newly diagnosed with OA<BR/>Severity: knee pain and limitation on most days of the past 6 months and Kellgren-Lawrence score II (31 patients) to III (36 patients)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-12 05:12:36 -0400" MODIFIED_BY="[Empty name]">
<P>Experimental intervention: continuous ultrasound therapy, five times per week<BR/>Control intervention: sham ultrasound therapy, five times per week</P>
<P>Duration of treatment period: 2 weeks<BR/>Analgesics were not allowed, two patients were dropped out from the control group due to analgesic intake</P>
<P>Device: Petson .250 ultrasound equipment<BR/>Duration of stimulation per session: 5 minutes<BR/>Total sessions: 10<BR/>Frequency: 1.00 MHz<BR/>Intensity: 1 W/cm2<BR/>Head size: 4 cm<BR/>Treated anatomical areas: patellofemoral and tibiofemoral borders of the target knee on both the lateral and medial margins, avoiding the patella<BR/>Area treated per session: 25cm<SUP>2</SUP>
<BR/>Skin prep: Aqueous gel<BR/>Safety precautions: circular movements</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-12 05:12:40 -0400" MODIFIED_BY="[Empty name]">
<P>Extracted pain outcome: WOMAC pain subscale at 2 weeks, 2 days <I>after</I> end of last treatment, measured on 0 to 20 Likert scale</P>
<P>Extracted function outcome: WOMAC physical function subscale at 2 weeks, 2 days <I>after</I> end of last treatment, measured on 0 to 68 Likert scale</P>
<P>Primary outcome reported: knee pain on movement over the past week, measured on 10 cm VAS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-07-22 05:24:17 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-02-23 11:58:09 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-02-20 11:08:59 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Antich-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-20 11:08:59 -0500" MODIFIED_BY="[Empty name]">
<P>Not osteoarthritis but several types of knee extensor mechanism<BR/>disorders described as chondromalacia patella, infrapatellar tendinitis and peripatellar pain. Additional description: RCT with 4-arm parallel group design comparing ice, phonophoresis, iontophoresis and ultrasound therapy + ice.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-18 12:50:07 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bansil-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-18 12:50:07 -0500" MODIFIED_BY="[Empty name]">
<P>Use of active control group. Additional description: RCT with 2 arm parallel group design comparing ultrasound therapy with shortwave diathermy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-18 13:42:09 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Esmat-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-18 13:42:09 -0500" MODIFIED_BY="[Empty name]">
<P>Use of active control group. Additional description: 3 arm parallel group design comparing ultrasound therapy to interferential current stimulation or ultrasound therapy with interferential current stimulation. Unclear whether allocation of treatment was at random.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-20 11:10:11 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jan-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-20 11:10:11 -0500" MODIFIED_BY="[Empty name]">
<P>Use of active control group. Additional description: RCT with 4 arm parallel group design comparing ultrasound therapy versus short wave diathermy or ultrasound therapy + exercise or diathermy + exercise.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-18 07:48:51 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jones-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-18 07:48:51 -0500" MODIFIED_BY="[Empty name]">
<P>No relevant outcome reported. Additional description: study design unclear and unclear whether people with osteoarthritis were included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-20 11:10:23 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lindahl-1952">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-20 11:10:23 -0500" MODIFIED_BY="[Empty name]">
<P>Unable to extract data for osteoarthritis. Additional description: RCT, parallel design, two arms comparing ultrasound therapy versus sham ultrasound therapy in people with chondromalacic and osteoarthritic knee conditions. Results presented jointly. No contact could be established with the author.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-18 11:59:23 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Machalett-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-18 11:59:23 -0500" MODIFIED_BY="[Empty name]">
<P>Not a randomised study (historical case series)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-20 11:10:34 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svarcova-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-20 11:10:34 -0500" MODIFIED_BY="[Empty name]">
<P>Use of active control groups. Additional description: controlled trial with groups receiving either Galvanic electrostimulation or ultrasound therapy or pulsed short wave diathermy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-18 12:17:43 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zielke-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-18 12:17:43 -0500" MODIFIED_BY="[Empty name]">
<P>Not a randomised study. Additional description: report summarising percentages of any type of active or passive treatment option given to patients with osteoarthritis during a course of treatment in the state health resorts Bad Brambach--Bad Elster in 1979 to 1981.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-10-12 05:14:09 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2009-10-12 05:14:09 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kostadinov-1978">
<CHAR_METHODS MODIFIED="2009-02-19 03:14:16 -0500" MODIFIED_BY="[Empty name]">
<P>Most likely comparative study with historical controls or cohort study.</P>
<P>Quote: 'An attempt is made for comparative assessment of the most commonly used physical factors in the treatment of gonarthrosis patients. The objects of the investigation were the widely used (in Bulgaria) physical factors (...)' </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-19 02:59:46 -0500" MODIFIED_BY="[Empty name]">
<P>427 in- and outpatients with osteoarthritis of the knee</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-19 02:58:37 -0500" MODIFIED_BY="[Empty name]">
<P>Mineral-oil electrophoresis and low frequency impulse currents<BR/>Device: Bipulsator, Magnetimpulsator and a bipolar electrostimulator</P>
<P>Interferential current (electro)stimulation</P>
<P>Therapeutic Ultrasound</P>
<P>Phonophoresis with hydrocortisone</P>
<P>Electrophoresis with KJ and novocaine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-10-12 05:14:09 -0400" MODIFIED_BY="[Empty name]">
<P>Awaiting translation</P>
<P>Function was described as 'locomotion'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-19 02:58:48 -0500" MODIFIED_BY="[Empty name]">
<P>Publication in Bulgarian. We have not yet been able to involve a Bulgarian translator.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-10-12 05:15:23 -0400" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-10-12 05:12:40 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:09:00 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cetin-2008">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:09:20 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Falconer-1992">
<DESCRIPTION>
<P>No information provided. In personal communication Dr Falconer indicated that permuted block randomisation was used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:09:53 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2005-A">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:11:45 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2005-B">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:12:40 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-_x00d6_zg_x00f6_nenel-2009">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-10-12 05:12:57 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:09:01 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cetin-2008">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:09:08 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Falconer-1992">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:10:36 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2005-A">
<DESCRIPTION>
<P>Although authors wrote that they used sequentially numbered opaque sealed envelopes, we had no evidence to suggest that the envelopes were appropriately numbered in a sequential manner and random allocation could therefore have been undermined. </P>
<P>Quote: 'and randomly assigned to 4 groups (groups I&#8211;IV) by a secure system of opaque sealed envelopes that were sequentially numbered I&#8211;IV. The doctor who assigned the patients was blinded to the treatment the patients would receive.'</P>
<P>With 140 patients randomised, the envelopes should have been sequentially numbered 1-140 and not I to IV.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:12:00 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2005-B">
<DESCRIPTION>
<P>Although authors wrote that they used sequentially numbered opaque sealed envelopes, we had no evidence to suggest that the envelopes were appropriately numbered in a sequential manner and random allocation could therefore have been undermined.</P>
<P>Quote: 'they were randomly assigned to 4 groups by a secure system of sequentially numbered I through IV opaque sealed envelopes. The physician who assigned the patients was blinded as to the treatment they would receive.'</P>
<P>With 120 patients randomised, the envelopes should have been sequentially numbered 1-120 and not I to IV.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:12:57 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-_x00d6_zg_x00f6_nenel-2009">
<DESCRIPTION>
<P>Authors merely state that "An independent researcher not involved in the data assessment randomized the subjects.".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2009-10-12 05:12:58 -0400" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Adequate blinding of patients?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:09:02 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cetin-2008">
<DESCRIPTION>
<P>No sham intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-19 11:06:24 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Falconer-1992">
<DESCRIPTION>
<P>Sham device: identical in appearance, dials were lit and audible beeps were given at each sham increase in dosage. No energy delivered to tissue.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:10:47 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huang-2005-A">
<DESCRIPTION>
<P>No sham intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-24 07:52:54 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huang-2005-B">
<DESCRIPTION>
<P>Sham intervention given in the control group, but the investigators stated '(...) however, the absence of a warm<BR/>or stinging sensation for the treated patients caused the failure of the sham US application.'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:12:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x00d6_zg_x00f6_nenel-2009">
<DESCRIPTION>
<P>Sham device: identical in appearance. Quotes: "An applicator disconnected from the back to working ultrasound machine". Patient in position unable to see whether the cable was disconnected or not.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2009-10-12 05:13:42 -0400" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Adequate blinding of physicians/physical therapists?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:09:24 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cetin-2008">
<DESCRIPTION>
<P>For safety reasons, the treating health care provider must be aware of the type of ultrasound therapy given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:09:09 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Falconer-1992">
<DESCRIPTION>
<P>For safety reasons, the treating health care provider must be aware of the type of ultrasound therapy given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:10:18 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huang-2005-A">
<DESCRIPTION>
<P>No sham intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:12:00 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huang-2005-B">
<DESCRIPTION>
<P>For safety reasons, the treating health care provider must be aware of the type of ultrasound therapy given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:13:42 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-_x00d6_zg_x00f6_nenel-2009">
<DESCRIPTION>
<P>For safety reasons, the treating health care provider must be aware of the type of ultrasound therapy given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2009-10-12 05:13:56 -0400" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Adequate blinding of outcome assessors?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-24 07:48:38 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cetin-2008">
<DESCRIPTION>
<P>Although the investigators wrote that 'Patients were evaluated at baseline and at the end of the treatment sessions<BR/>by the physician, who was blinded with regard to the type of treatment the patients would receive', VAS and Lequesne are likely to be self reported by patients, who were not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-19 10:49:53 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Falconer-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:11:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2005-A">
<DESCRIPTION>
<P>Quote: 'All the evaluations were performed by the same physiatrists who were also blinded to the treatment the patients received'. We scored unclear for both pain and function, however, as a VAS was used for pain, and Lequesne for function that are usually scored by the patient, who was not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:12:05 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huang-2005-B">
<DESCRIPTION>
<P>For Pain: VAS is usually scored by patients, who were not blinded. For function: no information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:13:56 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-_x00d6_zg_x00f6_nenel-2009">
<DESCRIPTION>
<P>Quote: "Both the therapeutic US and the sham US application were performed by the same therapist and patients were assessed by three blinded researchers before and at the end of therapy program". Pain and function were measured on WOMAC subscales, that are usually scored by the patient. In this trial, patients were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="GROUP" MODIFIED="2009-10-12 05:15:23 -0400" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Intention-to-treat analysis performed?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-10.01" NO="1">
<NAME>Pain</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-10.02" NO="2">
<NAME>Function</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2009-10-12 05:09:21 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cetin-2008">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2009-10-12 05:09:04 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cetin-2008">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2009-10-12 05:09:09 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Falconer-1992">
<DESCRIPTION>
<P>34 out of 37 (92%) randomised to experimental and 35 out of 37 (95%) randomised to control group were analysed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2009-10-12 05:09:33 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Falconer-1992">
<DESCRIPTION>
<P>Not applicable, trial did not contribute to function meta-analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2009-10-12 05:11:36 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huang-2005-A">
<DESCRIPTION>
<P>64 out of 70 (91%) randomised to experimental and 60 out of 70 (86%) randomised to control group were analysed (analysis on knee level).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2009-10-12 05:11:24 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huang-2005-A">
<DESCRIPTION>
<P>32 out of 35 (91%) randomised to experimental and 30 out of 35 (86%) randomised to control group were analysed (analysis on patient level).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2009-10-12 05:13:36 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huang-2005-B">
<DESCRIPTION>
<P>Comparison I: 54 out of 60 (90%) randomised to experimental and 50 out of 60 (83%) randomised to control group were analysed.</P>
<P>Comparison II: 60 out of 60 (100%) randomised to experimental and 50 out of 60 (83%) randomised to control group were analysed.</P>
<P>Analyses performed on knee level.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2009-10-12 05:15:23 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huang-2005-B">
<DESCRIPTION>
<P>Comparison I: 27 out of 30 (90%) randomised to experimental and 25 out of 30 (83%) randomised to control group were analysed.</P>
<P>Comparison II: 30 out of 30 (100%) randomised to experimental and 25 out of 30 (83%) randomised to control group were analysed.</P>
<P>Analyses performed on patient level.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2009-10-12 05:14:03 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-_x00d6_zg_x00f6_nenel-2009">
<DESCRIPTION>
<P>No information provided. It was only reported that "In the placebo group, two patients used analgesics because of increased pain and were thus dropped out of the study.".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2009-10-12 05:15:21 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-_x00d6_zg_x00f6_nenel-2009">
<DESCRIPTION>
<P>No information provided. It was only reported that "In the placebo group, two patients used analgesics because of increased pain and were thus dropped out of the study.".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2009-10-12 05:14:08 -0400" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Funding by commercial organisation avoided?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:09:05 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cetin-2008">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:09:33 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Falconer-1992">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:11:25 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2005-A">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:12:11 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2005-B">
<DESCRIPTION>
<P>Treatment equipment supplied by Chattecx group, ATL ultrasound and Enraf Nonius.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-12 05:14:08 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-_x00d6_zg_x00f6_nenel-2009">
<DESCRIPTION>
<P>No information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2009-07-24 07:44:15 -0400" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Funding by non-profit organisation?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2009-11-11 02:33:29 -0500" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2009-11-11 02:33:29 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-04-17 14:02:42 -0400" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Therapeutic ultrasound compared with sham or no specific intervention for patients with knee or hip osteoarthritis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>Patients with knee osteoarthritis (none of the trials included patients with hip osteoarthritis)</P>
<P>
<B>Settings: </B>Private physical therapy practice in USA (1 trial) and medical university hospital outpatient clinic in Taiwan (2 trials), and outpatient clinic of department of physical medicine and rehabilitation in Turkey (2 trials)</P>
<P>
<B>Intervention: </B>Therapeutic ultrasound</P>
<P>
<B>Comparison: </B>Sham or no specific intervention</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Sham or no specific intervention</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Therapeutic ultrasound</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>Pain</B>
</P>
<P>VAS pain scales</P>
<P>Follow-up: 2 to 8 weeks</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>-1.8 cm change</B> on 10 cm VAS<SUP>1</SUP>
</P>
<P>29% improvement</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>-3.0 cm change</B>
<BR/>(&#916; -1.2 cm, -1.9 to -0.6 cm)<SUP>2</SUP>
</P>
<P>50% improvement<BR/>(&#916; 21%, 10% to 32%)<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>SMD -0.49 (-0.76 to -0.23)</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>320<BR/>(5)<BR/>
</P>
</TD>
<TD ALIGN="CENTER">
<P>++OO<BR/>low<SUP>4</SUP>
</P>
</TD>
<TD>
<P>NNT: 6 (95% CI 5 to 12)<SUP>5</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>Function</B>
</P>
<P>Various validated function scales</P>
<P>Follow-up: 2 to 8 weeks</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>-1.2 units on WOMAC</B>
<BR/>(range 0 to 10)<SUP>1</SUP>
</P>
<P>21% improvement</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>-2.6 units on WOMAC</B>
<BR/>(&#916; -1.3, -3.0 to 0.3)<SUP>6</SUP>
</P>
<P>46% improvement</P>
<P>(&#916; 25%, -5% to 54%)<SUP>7</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>SMD -0.64 (-1.42 to 0.14)</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>251<BR/>(4)</P>
</TD>
<TD ALIGN="CENTER">
<P>++OO<BR/>low<SUP>8</SUP>
</P>
</TD>
<TD>
<P>Little evidence for a beneficial effect</P>
<P>[NNT: not statistically significant]</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>Number of patients experiencing any adverse event</B>
</P>
<P>Follow-up: 2 weeks</P>
</TD>
<TD ALIGN="CENTER">
<P>150 per 1000 patient-years<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>not estimable</P>
</TD>
<TD ALIGN="CENTER">
<P>67<BR/>(1)</P>
</TD>
<TD ALIGN="CENTER">
<P>++OO<BR/>low<SUP>9</SUP>
</P>
</TD>
<TD>
<P>0 events reported</P>
<P>NNH not estimable</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>Number of patients who withdrew because of adverse events</B>
</P>
<P>Follow-up: 2 weeks</P>
</TD>
<TD ALIGN="CENTER">
<P>17 per 1000 patient-years<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>not estimable</P>
</TD>
<TD ALIGN="CENTER">
<P>67<BR/>(1)</P>
</TD>
<TD ALIGN="CENTER">
<P>++OO<BR/>low<SUP>9</SUP>
</P>
</TD>
<TD>
<P>0 events reported</P>
<P>NNH not estimable</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>Number of patients experiencing any serious adverse event</B>
</P>
<P>Follow-up: 2 and 15 weeks</P>
</TD>
<TD ALIGN="CENTER">
<P>4 per 1000 patient-years<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER">
<P>not estimable</P>
</TD>
<TD ALIGN="CENTER">
<P>136<BR/>(2)</P>
</TD>
<TD ALIGN="CENTER">
<P>++OO<BR/>low<SUP>10</SUP>
</P>
</TD>
<TD>
<P>0 events reported</P>
<P>NNH not estimable</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; GRADE: GRADE Working Group grades of evidence (see explanations); SMD: standardised mean difference; NNT: number needed to treat; NNH; number needed to harm</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality (++++):</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality (+++O):</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality (++OO):</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality (+OOO):</B> We are very uncertain about the estimate.</P>
<P>
<SUP>1</SUP> Median reduction as observed across placebo groups in large osteoarthritis trials (see methods section, <LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>).<BR/>
<SUP>2</SUP> Standardised mean differences (SMDs) were back-transformed onto a 10 cm visual analogue scale (VAS) on the basis of a typical pooled SD of 2.5 cm in large trials that assessed pain using a VAS and expressed as change based on an assumed standardised reduction of 0.72 standard deviation units in the control group.<BR/>
<SUP>3</SUP> Percentage of improvement was calculated based on median observed pain at baseline across control groups of large osteoarthritis trials of 6.1 cm on 10 cm VAS (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>).<BR/>
<SUP>4</SUP> Downgraded (2 levels) because included trials were generally of low quality and small sample size: analyses was not according to intention to treat principle in at least 3 trials; concealment of allocation methods was unclear in all trials; and the possible indirectness of evidence (indirect population) in 1 trial.<BR/>
<SUP>5</SUP> Absolute response risks for pain in the control groups were assumed 31% (see methods section).<BR/>
<SUP>6</SUP> Standardised mean differences (SMDs) were back-transformed onto a standardised WOMAC disability score ranging from 0 to 10 on the basis of a typical pooled SD of 2.1 in trials that assessed function using WOMAC disability scores and expressed as change based on an assumed standardised reduction of 0.58 standard deviation units in the control group.<BR/>
<SUP>7 </SUP>Percentage of improvement was calculated based on median observed WOMAC function scores at baseline across control groups of large osteoarthritis trials of 5.6 units (<LINK REF="REF-N_x00fc_esch-2009" TYPE="REFERENCE">Nüesch 2009</LINK>).<BR/>
<SUP>8</SUP> Downgraded (2 levels) because included trials were generally of low quality and small sample size: analyses was not according to intention to treat principle in at least 2 trials; concealment of allocation methods was unclear in all trials; inadequate patient blinding in 3 trials, possible indirectness of evidence (indirect population) in 1 trial, the presence of large between trial heterogeneity and the confidence interval crossed no difference.<BR/>
<SUP>9</SUP> Downgraded (2 levels) because of: small sample size, due to absence of events, no relative risk could be calculated, 1 out of 5 studies reported this outcome, possibly leading<BR/>to selective outcome reporting bias.</P>
<P>
<SUP>10</SUP> Downgraded (2 levels) because of: small sample size, due to absence of events, no relative risk could be calculated, 2 out of 5 studies reported this outcome, possibly leading to selective outcome reporting bias.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2009-10-12 03:25:49 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-10-12 03:22:58 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-08-24 14:57:51 -0400" MODIFIED_BY="[Empty name]">Results of stratified analyses of pain outcomes</TITLE>
<TABLE COLS="7" ROWS="31">
<TR>
<TH>
<P>
<B>Variable</B>
</P>
</TH>
<TH>
<P>
<B>No. of trials</B>
</P>
</TH>
<TH>
<P>
<B>No. of patients: experimental</B>
</P>
</TH>
<TH>
<P>
<B>No. of patients:</B>
<BR/>
<B>control</B>
</P>
</TH>
<TH>
<P>
<B>Pain-intensity</B>
</P>
</TH>
<TH>
<P>
<B>Heterogeneity</B>
</P>
</TH>
<TH>
<P>
<B>P for interaction</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>n</P>
</TD>
<TD>
<P>n</P>
</TD>
<TD>
<P>n</P>
</TD>
<TD>
<P>SMD (95% CI)</P>
</TD>
<TD>
<P>I<SUP>2</SUP> (%)</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>All trials</B>
</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P>177</P>
</TD>
<TD>
<P>143</P>
</TD>
<TD>
<P>-0.49 (-0.76 to -0.23)</P>
</TD>
<TD>
<P>26%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Type of control intervention</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.8</P>
</TD>
</TR>
<TR>
<TD>
<P>Sham intervention</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>125</P>
</TD>
<TD>
<P>93</P>
</TD>
<TD>
<P>-0.52 (-0.80 to -0.24)</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>No control intervention</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>-0.40 (-1.24 to 0.44)</P>
</TD>
<TD>
<P>77%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Blinding of patients</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.71</P>
</TD>
</TR>
<TR>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>68</P>
</TD>
<TD>
<P>68</P>
</TD>
<TD>
<P>-0.42 (-0.76 to -0.08)</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Inadequate or unclear</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>109</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>-0.52 (-1.01 to -0.04)</P>
</TD>
<TD>
<P>60%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Blinding of outcome assessor</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.71</P>
</TD>
</TR>
<TR>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>68</P>
</TD>
<TD>
<P>68</P>
</TD>
<TD>
<P>-0.42 (-0.76 to -0.08)</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Inadequate or unclear</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>109</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>-0.52 (-1.01 to -0.04)</P>
</TD>
<TD>
<P>60%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Type of Ultrasound&#8224;</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.48</P>
</TD>
</TR>
<TR>
<TD>
<P>Continuous</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>81</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P>-0.39 (-0.80 to 0.02)</P>
</TD>
<TD>
<P>45%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pulsed</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>96</P>
</TD>
<TD>
<P>78</P>
</TD>
<TD>
<P>-0.62 (-0.97 to -0.26)</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Duration of US per session</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.15&#8225;</P>
</TD>
</TR>
<TR>
<TD>
<P>5 minutes</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>-0.38 (-0.87 to 0.11)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>10 minutes</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>0.04 (-0.58 to 0.66)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>12 minutes</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>-0.45 (-0.93 to 0.03)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>15 minutes</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>89</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>-0.77 (-1.11 to -0.41)</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Total number of sessions</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.69&#8225;</P>
</TD>
</TR>
<TR>
<TD>
<P>10</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>-0.38 (-0.87 to 0.11)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>12</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>-0.45 (-0.93 to 0.03)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>24</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>109</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>-0.52 (-1.01 to -0.04)</P>
</TD>
<TD>
<P>60%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Duration of treatment period</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.69&#8225;</P>
</TD>
</TR>
<TR>
<TD>
<P>2 weeks</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>-0.38 (-0.87 to 0.11)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>6 weeks</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>35</P>
</TD>
<TD>
<P>-0.45 (-0.93 to 0.03)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>8 weeks</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>109</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>-0.52 (-1.01 to -0.04)</P>
</TD>
<TD>
<P>60%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Commercial funding</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.45</P>
</TD>
</TR>
<TR>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>-0.72 (-1.20 to -0.23)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>No or unclear</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>120</P>
</TD>
<TD>
<P>118</P>
</TD>
<TD>
<P>-0.43 (-0.74 to -0.11)</P>
</TD>
<TD>
<P>31%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>US: Ultrasound therapy; No.: number; N/A: not applicable; &#8224;<LINK REF="STD-Huang-2005-B" TYPE="STUDY">Huang 2005 B</LINK> contributed to both strata, with the same 25 control patients displayed in each stratum; &#8225;, P-value from test for trend.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2009-10-12 03:25:49 -0400" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-08-24 14:58:07 -0400" MODIFIED_BY="[Empty name]">Results of stratified analyses of function</TITLE>
<TABLE COLS="7" ROWS="31">
<TR>
<TH>
<P>
<B>Variable</B>
</P>
</TH>
<TH>
<P>
<B>No. of trials</B>
</P>
</TH>
<TH>
<P>
<B>No. of patients: experimental</B>
</P>
</TH>
<TH>
<P>
<B>No. of patients:</B>
<BR/>
<B>control</B>
</P>
</TH>
<TH>
<P>
<B>Pain-intensity</B>
</P>
</TH>
<TH>
<P>
<B>Heterogeneity</B>
</P>
</TH>
<TH>
<P>
<B>P for interaction</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>n</P>
</TD>
<TD>
<P>n</P>
</TD>
<TD>
<P>n</P>
</TD>
<TD>
<P>SMD (95% CI)</P>
</TD>
<TD>
<P>I<SUP>2</SUP> (%)</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>All trials</B>
</P>
</TD>
<TD>
<P>4</P>
</TD>
<TD>
<P>143</P>
</TD>
<TD>
<P>108</P>
</TD>
<TD>
<P>-0.64 (-1.42 to0.14)</P>
</TD>
<TD>
<P>88%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Type of control intervention</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.93</P>
</TD>
</TR>
<TR>
<TD>
<P>Sham intervention</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>91</P>
</TD>
<TD>
<P>58</P>
</TD>
<TD>
<P>-0.58 (-1.20 to 0.03)</P>
</TD>
<TD>
<P>69%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>No control intervention</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>-0.68 (-2.66 to 1.29)</P>
</TD>
<TD>
<P>95%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Blinding of patients</B>
</P>
</TD>
<TD>
<P/>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.70</P>
</TD>
</TR>
<TR>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>-0.27 (-0.76 to 0.22)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Inadequate or unclear</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>109</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>-0.76 (-1.83 to 0.31)</P>
</TD>
<TD>
<P>94%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Blinding of outcome assessor</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.52</P>
</TD>
</TR>
<TR>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>-0.97 (-2.35 to 0.42)</P>
</TD>
<TD>
<P>93%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Inadequate or unclear</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>77</P>
</TD>
<TD>
<P>45</P>
</TD>
<TD>
<P>-0.30 (-1.50 to 0.90)</P>
</TD>
<TD>
<P>89%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Type of Ultrasound&#8224;</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.005</P>
</TD>
</TR>
<TR>
<TD>
<P>Continuous</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>81</P>
</TD>
<TD>
<P>65</P>
</TD>
<TD>
<P>-0.15 (-0.56 to 0.26)</P>
</TD>
<TD>
<P>41%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Pulsed</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>62</P>
</TD>
<TD>
<P>43</P>
</TD>
<TD>
<P>-1.58 (-2.00 to -1.16)</P>
</TD>
<TD>
<P>0%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Duration of US per session</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.16&#8225;</P>
</TD>
</TR>
<TR>
<TD>
<P>5 minutes</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>-0.27 (-0.76 to 0.22)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>10 minutes</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>0.33 (-0.30 to 0.95)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>12 minutes</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>15 minutes</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>89</P>
</TD>
<TD>
<P>55</P>
</TD>
<TD>
<P>-1.28 (-2.05 to -0.51)</P>
</TD>
<TD>
<P>76%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Total number of sessions</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.70</P>
</TD>
</TR>
<TR>
<TD>
<P>10</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>-0.27 (-0.76 to 0.22)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>12</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>24</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>109</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>-0.76 (-1.83 to 0.31)</P>
</TD>
<TD>
<P>91%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Duration of treatment period</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.70</P>
</TD>
</TR>
<TR>
<TD>
<P>2 weeks</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>34</P>
</TD>
<TD>
<P>33</P>
</TD>
<TD>
<P>-0.27 (-0.76 to 0.22)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>6 weeks</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>8 weeks</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>109</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>-0.76 (-1.83 to 0.31)</P>
</TD>
<TD>
<P>94%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Commercial funding</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.78</P>
</TD>
</TR>
<TR>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>57</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>-0.90 (-1.39 to -0.41)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>No or unclear</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>86</P>
</TD>
<TD>
<P>83</P>
</TD>
<TD>
<P>-0.54 (-1.65 to 0.56)</P>
</TD>
<TD>
<P>91%</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>US: Ultrasound therapy; No.: number; N/A: not applicable; &#8224;<LINK REF="STD-Huang-2005-B" TYPE="STUDY">Huang 2005 B</LINK> contributed to both strata, with the same 25 control patients displayed in each stratum; &#8225; P-value from test for trend.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-07-24 07:42:26 -0400" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-07-24 07:42:26 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Any type of therapeutic ultrasound versus control</NAME>
<IV_OUTCOME CHI2="5.423863468425919" CI_END="-0.2255071689543956" CI_START="-0.7587305646111453" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_SIZE="-0.49211886678277045" ESTIMABLE="YES" I2="26.251830945131523" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-07-23 05:57:16 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2465036375307741" P_Q="1.0" P_Z="2.9717185329852623E-4" Q="0.0" RANDOM="YES" SCALE="4.6" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.024271024546827568" TOTALS="YES" TOTAL_1="177" TOTAL_2="143" WEIGHT="100.0" Z="3.6177529450631694">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ultrasound</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="0.6771884750528174" CI_START="-0.5771884750528173" EFFECT_SIZE="0.05" ESTIMABLE="YES" ESTIMATE="0.05" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-23 05:57:16 -0400" MODIFIED_BY="[Empty name]" ORDER="50" SE="0.32" STUDY_ID="STD-Cetin-2008" TOTAL_1="20" TOTAL_2="20" WEIGHT="14.60780409216416"/>
<IV_DATA CI_END="0.020391356289612972" CI_START="-0.920391356289613" EFFECT_SIZE="-0.45" ESTIMABLE="YES" ESTIMATE="-0.45" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-23 05:57:16 -0400" MODIFIED_BY="[Empty name]" ORDER="48" SE="0.24" STUDY_ID="STD-Falconer-1992" TOTAL_1="34" TOTAL_2="35" WEIGHT="22.601225781355822"/>
<IV_DATA CI_END="-0.30040936401958596" CI_START="-1.3195906359804142" EFFECT_SIZE="-0.81" ESTIMABLE="YES" ESTIMATE="-0.81" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-23 05:57:16 -0400" MODIFIED_BY="[Empty name]" ORDER="51" SE="0.26" STUDY_ID="STD-Huang-2005-A" TOTAL_1="32" TOTAL_2="30" WEIGHT="20.14112196811972"/>
<IV_DATA CI_END="-0.2300090038649864" CI_START="-1.2099909961350135" EFFECT_SIZE="-0.72" ESTIMABLE="YES" ESTIMATE="-0.72" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-23 05:57:16 -0400" MODIFIED_BY="[Empty name]" ORDER="52" SE="0.25" STUDY_ID="STD-Huang-2005-B" TOTAL_1="57" TOTAL_2="25" WEIGHT="21.324924079180146"/>
<IV_DATA CI_END="0.10999099613501356" CI_START="-0.8699909961350136" EFFECT_SIZE="-0.38" ESTIMABLE="YES" ESTIMATE="-0.38" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-23 05:57:16 -0400" MODIFIED_BY="[Empty name]" ORDER="51" SE="0.25" STUDY_ID="STD-_x00d6_zg_x00f6_nenel-2009" TOTAL_1="34" TOTAL_2="33" WEIGHT="21.324924079180146"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="24.706914220047942" CI_END="0.1447986169422658" CI_START="-1.4166326005636725" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="-0.6359169918107033" ESTIMABLE="YES" I2="87.85764999513493" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.8392355863240287" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2009-07-24 07:32:00 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.7780042182335976E-5" P_Q="1.0" P_Z="0.11038808402400639" Q="0.0" RANDOM="YES" SCALE="4.6" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.5557972398765209" TOTALS="YES" TOTAL_1="143" TOTAL_2="108" WEIGHT="99.99999999999999" Z="1.5964512392634944">
<NAME>Function</NAME>
<GROUP_LABEL_1>Ultrasound</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ultrasound</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="0.9571884750528175" CI_START="-0.29718847505281737" EFFECT_SIZE="0.33" ESTIMABLE="YES" ESTIMATE="0.33" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-23 05:57:52 -0400" MODIFIED_BY="[Empty name]" ORDER="53" SE="0.32" STUDY_ID="STD-Cetin-2008" TOTAL_1="20" TOTAL_2="20" WEIGHT="24.106462562764207"/>
<IV_DATA CI_END="-1.1020108046379837" CI_START="-2.277989195362016" EFFECT_SIZE="-1.69" ESTIMABLE="YES" ESTIMATE="-1.69" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-23 05:57:52 -0400" MODIFIED_BY="[Empty name]" ORDER="54" SE="0.3" STUDY_ID="STD-Huang-2005-A" TOTAL_1="32" TOTAL_2="30" WEIGHT="24.569332512216814"/>
<IV_DATA CI_END="-0.41000900386498645" CI_START="-1.3899909961350136" EFFECT_SIZE="-0.9" ESTIMABLE="YES" ESTIMATE="-0.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-23 05:57:52 -0400" MODIFIED_BY="[Empty name]" ORDER="55" SE="0.25" STUDY_ID="STD-Huang-2005-B" TOTAL_1="57" TOTAL_2="25" WEIGHT="25.662102462509484"/>
<IV_DATA CI_END="0.21999099613501355" CI_START="-0.7599909961350135" EFFECT_SIZE="-0.27" ESTIMABLE="YES" ESTIMATE="-0.27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-23 05:57:52 -0400" MODIFIED_BY="[Empty name]" ORDER="52" SE="0.25" STUDY_ID="STD-_x00d6_zg_x00f6_nenel-2009" TOTAL_1="34" TOTAL_2="33" WEIGHT="25.662102462509484"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2009-07-24 07:42:17 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="33" WEIGHT="0.0" Z="0.0">
<NAME>Number of patients experiencing any adverse event</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-23 05:58:31 -0400" MODIFIED_BY="[Empty name]" ORDER="36" O_E="0.0" SE="0.0" STUDY_ID="STD-_x00d6_zg_x00f6_nenel-2009" TOTAL_1="34" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2009-07-24 07:42:26 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="33" WEIGHT="0.0" Z="0.0">
<NAME>Number of patients withdrawn or dropped out due to adverse events</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-23 05:59:00 -0400" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="0.0" STUDY_ID="STD-_x00d6_zg_x00f6_nenel-2009" TOTAL_1="34" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="IV" MODIFIED="2009-07-24 07:37:27 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="68" TOTAL_2="68" WEIGHT="0.0" Z="0.0">
<NAME>Number of patients experiencing any serious adverse event</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-23 05:59:43 -0400" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.0" STUDY_ID="STD-Falconer-1992" TOTAL_1="34" TOTAL_2="35" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-23 05:59:46 -0400" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="0.0" STUDY_ID="STD-_x00d6_zg_x00f6_nenel-2009" TOTAL_1="34" TOTAL_2="33" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-10-12 05:15:24 -0400" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flow-chart-US_7August2009.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-08-24 11:58:22 -0400" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow chart</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAkIAAAHACAYAAABONwdOAAB02ElEQVR42uydB5wURdr/a5clLJIV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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-10-12 05:15:24 -0400" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological characteristics and source of funding of included trials. (+) indicates low risk of bias, (?) unclear and (-) a high risk of bias on a specific item.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAWMAAAHOCAIAAADCIv+GAAAXrUlEQVR42u3dvY4cx9nF8QWcONiA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2009-10-12 03:27:00 -0400" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of 5 trials comparing the effects of therapeutic ultrasound and control (sham or no intervention) on knee pain. Values on x-axis denote standardised mean differences. Data relating to the 2 experimental arms in Huang 2005 B were pooled.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAz8AAADACAMAAAAdpy0gAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel_plot_pain_v1.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2009-10-12 03:27:08 -0400" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot for effects on knee pain.<BR/>Numbers on x-axis refer to standardised mean differences (SMDs), on y-axis to standard errors of SMDs.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAj4AAAGhCAYAAABh6r6nAAA+7ElEQVR42u2dB5gUZbpG/5lhCJKT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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2009-10-12 03:27:12 -0400" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of 3 trials comparing the effects of therapeutic ultrasound and control (sham or no intervention) on function. Values on x-axis denote standardised mean differences. Data relating to the 2 experimental arms in Huang 2005 B were pooled.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzIAAACwCAMAAADje6tRAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel_plot_function_v1.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2009-10-12 03:27:21 -0400" MODIFIED_BY="[Empty name]" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot for effects on functioning of the knee.<BR/>Numbers on x-axis refer to standardised mean differences (SMDs), on y-axis to standard errors of SMDs.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAk8AAAGtCAYAAAAPo5B6AAAnKklEQVR42u3dCZQcdaGo8SKQBEIC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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-10-09 10:29:19 -0400" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2009-02-20 11:05:54 -0500" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-02-20 11:05:54 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-02-20 09:52:58 -0500" MODIFIED_BY="[Empty name]">MEDLINE, EMBASE and Cinahl search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-20 11:05:54 -0500" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="5">
<TR>
<TD VALIGN="TOP">
<P>
<B>OVID MEDLINE</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>OVID EMBASE</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>CINAHL through EBSCOhost</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Search terms for design </I>
</P>
<P>1. randomized controlled trial.pt.<BR/>2. controlled clinical trial.pt.<BR/>3. randomized controlled trial.sh.<BR/>4. random allocation.sh.<BR/>5. double blind method.sh.<BR/>6. single blind method.sh.<BR/>7. clinical trial.pt.<BR/>8. exp clinical trial/<BR/>9. (clin$ adj25 trial$).ti,ab.<BR/>10. ((singl$ or doubl$ or trebl$ or<BR/>tripl$) adj25 (blind$ or mask$)).ti,ab.<BR/>11. placebos.sh.<BR/>12. placebo$.ti,ab.<BR/>13. random$.ti,ab.<BR/>14. research design.sh.<BR/>15. comparative study.sh.<BR/>16. exp evaluation studies/<BR/>17. follow up studies.sh.<BR/>18. prospective studies.sh.<BR/>19. (control$ or prospectiv$ or<BR/>volunteer$).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Search terms for design</I>
</P>
<P>1. randomized controlled trial.sh.<BR/>2. randomization.sh.<BR/>3. double blind procedure.sh.<BR/>4. single blind procedure.sh.<BR/>5. exp clinical trials/<BR/>6. (clin$ adj25 trial$).ti,ab.<BR/>7. ((singl$ or doubl$ or trebl$ or<BR/>tripl$) adj25<BR/>(blind$ or mask$)).ti,ab.<BR/>8. placebo.sh.<BR/>9. placebo$.ti,ab.<BR/>10. random$.ti,ab.<BR/>11. methodology.sh.<BR/>12. comparative study.sh.<BR/>13. exp evaluation studies/<BR/>14. follow up.sh.<BR/>15. prospective study.sh.<BR/>16. (control$ or prospectiv$ or<BR/>volunteer$).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Search terms for design</I>
</P>
<P>1. (MH "Clinical Trials+")<BR/>2. (MH "Random Assignment")<BR/>3. (MH "Double-Blind Studies") or<BR/>(MH "Single-Blind Studies")<BR/>4. TX (clin$ n25 trial$)<BR/>5. TX (sing$ n25 blind$)<BR/>6. TX (sing$ n25 mask$)<BR/>7. TX (doubl$ n25 blind$)<BR/>8. TX (doubl$ n25 mask$)<BR/>9. TX (trebl$ n25 blind$)<BR/>10. TX (trebl$ n25 mask$)<BR/>11. TX (tripl$ n25 blind$)<BR/>12. TX (tripl$ n25 mask$)<BR/>13. (MH "Placebos")<BR/>14. TX placebo$<BR/>15. TX random$<BR/>16. (MH "Study Design+")<BR/>17. (MH "Comparative Studies")<BR/>18. (MH "Evaluation Research")<BR/>19. (MH "Prospective Studies+")<BR/>20. TX (control$ or prospectiv$ or<BR/>volunteer$)<BR/>21. S1 or S2 or (&#8230;&#8230;.) or S20</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Search terms for Osteoarthritis</I>
</P>
<P>20. exp osteoarthritis/<BR/>21. osteoarthriti$.ti,ab,sh.<BR/>22. osteoarthro$.ti,ab,sh.<BR/>23. gonarthriti$.ti,ab,sh.<BR/>24. gonarthro$.ti,ab,sh.<BR/>25. coxarthriti$.ti,ab,sh.<BR/>26. coxarthro$.ti,ab,sh.<BR/>27. arthros$.ti,ab.<BR/>28. arthrot$.ti,ab.<BR/>29. ((knee$ or hip$ or joint$) adj3 <BR/>(pain$ or ach$ or discomfort$)).ti,ab.<BR/>30. ((knee$ or hip$ or joint$) adj3 stiff$).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Search terms for Osteoarthritis</I>
</P>
<P>17. exp osteoarthritis/<BR/>18. osteoarthriti$.ti,ab,sh.<BR/>19. osteoarthro$.ti,ab,sh.<BR/>20. gonarthriti$.ti,ab,sh.<BR/>21. gonarthro$.ti,ab,sh.<BR/>22. coxarthriti$.ti,ab,sh.<BR/>23. coxarthro$.ti,ab,sh.<BR/>24. arthros$.ti,ab.<BR/>25. arthrot$.ti,ab.<BR/>26. ((knee$ or hip$ or joint$) adj3<BR/>(pain$ or ach$ or<BR/>discomfort$)).ti,ab.<BR/>27. ((knee$ or hip$ or joint$) adj3<BR/>stiff$).ti,ab.</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Search terms for Osteoarthritis</I>
</P>
<P>22. osteoarthriti$<BR/>23. (MH "Osteoarthritis")<BR/>24. TX osteoarthro$<BR/>25. TX gonarthriti$<BR/>26. TX gonarthro$<BR/>27. TX coxarthriti$<BR/>28. TX coxarthro$<BR/>29. TX arthros$<BR/>30. TX arthrot$<BR/>31. TX knee$ n3 pain$<BR/>32. TX hip$ n3 pain$<BR/>33. TX joint$ n3 pain$<BR/>34. TX knee$ n3 ach$<BR/>35. TX hip$ n3 ach$<BR/>36. TX joint$ n3 ach$<BR/>37. TX knee$ n3 discomfort$<BR/>38. TX hip$ n3 discomfort$<BR/>39. TX joint$ n3 discomfort$<BR/>40. TX knee$ n3 stiff$<BR/>41. TX hip$ n3 stiff$<BR/>42. TX joint$ n3 stiff$<BR/>43. S22 or S23 or S24&#8230;.or S42</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Search terms for Therapeutic Ultrasound</I>
</P>
<P>31. exp ultrasonography/<BR/>32. exp Ultrasonic Therapy/<BR/>33. us.fs.<BR/>34. (ultrasound$ or ultrasonic$).tw.<BR/>35. short wave therapy.tw.<BR/>36. ultrasonograph$.tw.</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Search terms for Therapeutic Ultrasound </I>
</P>
<P>28. exp ultrasonography/<BR/>29. exp Ultrasonic Therapy/<BR/>30. (ultrasound$ or ultrasonic$).tw.<BR/>31. short wave therapy.tw.<BR/>32. ultrasonograph$.tw.</P>
<P/>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<I>Search terms for Therapeutic Ultrasound </I>
</P>
<P>44     exp ULTRASONOGRAPHY/<BR/>45     exp Ultrasonic Therapy/<BR/>46     (ultrasound$ or ultrasonic$).tw.<BR/>47     short wave therapy.tw.<BR/>48     ultrasonograph$.tw.<BR/>49     S44 or S45 or (...) or S48</P>
<P/>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Combining terms</I>
</P>
<P>37. or/1-19<BR/>38. or/20-30<BR/>39. or/31-36<BR/>40. and/37-39<BR/>41. animal/<BR/>42. animal/ and human/<BR/>43. 41 not 42<BR/>44. 40 not 43</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Combining terms</I>
</P>
<P>33. or/1-16<BR/>34. or/17-27<BR/>35. or/28-32<BR/>36. and/33-35<BR/>37. animal/<BR/>38. animal/ and human/<BR/>39. 37 not 38<BR/>40. 36 not 39</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>Combining terms</I>
</P>
<P>S21 and S43 and S49</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-02-20 10:15:35 -0500" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-02-20 10:06:39 -0500" MODIFIED_BY="[Empty name]">CENTRAL and PEDro search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-20 10:15:35 -0500" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="2">
<TR>
<TD VALIGN="TOP">
<P>
<B>CENTRAL</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>PEDro</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<I>Search terms for Osteoarthritis</I>
</P>
<P>#1. (osteoarthritis* OR osteoarthro* OR gonarthriti* OR gonarthro*<BR/>OR coxarthriti* OR coxarthro* OR arthros* OR arthrot* OR<BR/>((knee* OR hip* OR joint*) near/3 (pain* OR ach* OR discomfort*))<BR/>OR ((knee* OR hip* OR joint*) near/3 stiff*)) in Clinical Trials</P>
<P>#2. MeSH descriptor Osteoarthritis explode all trees</P>
<P>
<I>Search terms for TENS</I>
</P>
<P>#3 short wave therapy in Clinical Trials<BR/>#4 ultrasonograph in Clinical Trials<BR/>#5 (ultrasound* or ultrasonic*) in Clinical Trials<BR/>#6 MeSH descriptor Ultrasonography explode all trees<BR/>#7 MeSH descriptor Short-Wave Therapy explode all trees</P>
<P>Combining terms</P>
<P>#8. (#3 OR #4 OR #5 OR #6 OR #7)<BR/>#9. (#1 OR #2)<BR/>#10. (#8 AND #9) in Clinical Trials</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>1. Ultra in title or abstract<BR/>2. Method: clinical trial<BR/>3. Body part: thigh or hip<BR/>4. Body part lower leg or knee</P>
<P>Combination 1. and 2. and 3.<BR/>Combination 1. and 2. and 4.</P>
<P>1. short wave therapy in title or abstract<BR/>2. Method: clinical trial<BR/>3. Body part: thigh or hip<BR/>4. Body part lower leg or knee</P>
<P>Combination 1. and 2. and 3.<BR/>Combination 1. and 2. and 4.</P>
<P>Combine all</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2009-07-23 05:40:30 -0400" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>